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Abstract 
A complicated history of opioid use (uncontrolled dose escalation, drug-
seeking behaviours etc.) is thought to contraindicate the long-term use of 
opioids for people with chronic pain. In addition, many pain management 
programmes consider detoxification from opioids mandatory if chronic pain 
is to be successfully treated. In order to investigate this assumption a group of 
people displaying co-morbid chronic pain and drug addiction ( as defined by 
Portenoy, 1990) participated in the standard Burwood multi-disciplinary pain 
management programme. The subject group of seven males had an average 
age of 35 (S.D.=6.55) and an average pain duration of 139 months (S.D.=70.2). 
The participants were assessed at pre-treatment, post-treatment and two 
month follow-up using the Beck Depression Inventory (BDI), 
Multidimensional Pain Inventory (MPI), Cognitive Error Questionnaire 
(CEQ), Coping Strategies Questionnaire (CSQ) and Pain Locus of Control Scale 
(PLoC). Significant changes in outcome measures were observed in this 
previously considered untreatable group. Significant differences were also 
found with a control group of three males and three females (average age of 
40 (S.D.=7.88) and an average pain duration of 42 months (S.D.=22.91)) but not 
with the Burwood database results (which included all participants in the 
programme with complete data from February 199luntil February 1992) for 
the BDI and MPL 
Vl 
Literature Review 
Chronic pain is a major health problem that affects the lives of many 
thousands of New Zealanders. No figures are available on the extent of 
chronic pain in New Zealand although a study by James, Large, Bushnell & 
Wells (1991) reports that over 80% of adult New Zealanders have had pain 
that interfered with their life or activities 'a lot'. Although no accurate figures 
are available, Bonica (1990a) stated that evidence suggests that in the United 
States and other industrialised nations 25-30% of the population suffer from 
chronic pain. Nicholas (1992) suggests that 10% of the population experience 
chronic pain at any one time. 
Pain is by far the most common reason for people to seek help from a 
physician (Melzack & Wall, 1988). "Pain is a major plague that saps the 
strength of society" (Melzack, 1988; p. 10). This means that not only is pain a 
major health issue but also, because chronic pain impairs the ability to carry 
out a productive life, it is a serious economic problem as well. Burry & 
Gravis (1988) report that of those people who receive Accident Compensation 
Corporation payments in New Zealand, the 5.3% who had been off work for 
six months or more with back injuries received 50% of the total 
compensation payments. 
General Considerations of Chronic Pain 
Many people consider chronic pain to be pain that persists for more 
than 6 months (Black, 1975). This is an arbitrary time period and some people 
consider a set period of time to be inappropriate. Bonica (1990a) suggests that 
chronic pain is pain that persists one month beyond the usual course of an 
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acute disease or a reasonable time for an injury to heal, or that is associated 
with a chronic pathological process that causes continuous pain or the pain 
recurs at intervals for months or years. Bonica argues that one of the clinical 
implications of this definition is that rather than wait 6 months before 
intervening, efforts should be made to inhibit the development of chronic 
pain as soon as possible after the normal period of recovery. 
Pain from an acute injury has a clear purpose, to warn the body to 
protect itself and seek help, and to learn not to repeat the experience. Chronic 
pain, on the other hand, delivers no beneficial message. No longer a 
symptom of disease, pain becomes a disease itself as the person's life begins to 
revolve around their suffering (Stark, 1985). This is a fundamental 
difference: acute pain serves a useful purpose and chronic pain does not. 
There is no universally accepted definition for the word pain partly because 
the word represents a vast category of varying experiences. Merskey et al. 
(1986, in Melzack & Wall (1988)) define pain as an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage. This definition recognises the loose 
association between actual damage and pain and the role of emotional 
experience in the perception of pain. The prevalence of chronic pain in so 
many disorders of varying etiology does not allow for a single explanatory 
mechanism. 
Pain is a perceptual experience whose quality and intensity are 
influenced by the unique past history of the individual, by the meaning they 
give to the pain producing situation and by their 'state of mind' at the 
moment (Melzack & Wall, 1988; p. 32). Pain is a personal experience, it is not 
possible to know what someone else's pain feels like. For example, no man 
will ever know what it is like to suffer the pain of childbirth. 
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The phenomenon of pain can be divided into four domains: 
nociception, pain, suffering, and pain behaviour (Loeser & Egan, 1989). 
Nociception is the detection of tissue damage and the central propagation of 
this information via A delta and C fibres in the peripheral nerves (For a 
detailed consideration of the anatomical and physiologic basis of nociception 
and pain, refer Bonica, 199Gb). Pain is the recognition of these signals by the 
central nervous system (or problems within the nervous system which 
suggests tissue damage). Suffering is the negative affective response to pain 
or other emotionally laden events such as anxiety or depression. In many 
people with pain and these other events that contribute to suffering, the 
language of pain is used to describe the suffering and they are diagnosed as if 
the only cause were tissue damage. This can lead to inappropriate treatment; 
for example, the prescription of opioids to treat expressed suffering that may 
be enhanced by anxiety or depression. Pain behaviour is what a person does 
or does not do or say that leads the observer to infer that the subject is 
suffering from a noxious stimulus. 
The first three domains are internal private features of the pain 
experience. In many cases (but not all) the amount of pain that an individual 
should be experiencing can be estimated in proportion to the amount of 
damage that is evident. As we have seen however, the level of suffering that 
an individual experiences is dependent on a number of factors apart from just 
physical damage. Regardless of the physical processes involved, psychological 
and environmental factors also play a major role. The idea that other factors 
apart from physical damage can influence the perception of pain has received 
relatively little attention until the last few years. 
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The Evolution of Pain Theories 
The traditional theory of pain is known as 'specificity theory' and the 
best classical description of the theory was provided by Descartes in 1664. This 
approach conceptualised the experience of pain as a purely sensory 
phenomenon determined exclusively by the amount of physical damage 
present. Specificity theory proposes that a specific pain system carries 
messages from pain receptors in the skin directly to a pain centre in the brain 
(see Melzack & Wall (1988) for a detailed analysis of the development of 
specificity theory). The Cartesian view of pain gained ascendance in the late 
1800' s with advances in sensory physiology and psychophysics. Psychological 
factors, when considered at all, were relegated to positions of secondary 
interest (Turk & Rudy, 1986) and considered to be reactions to pain. For a 
more thorough examination of the early theories of pain refer Bonica (1990c). 
Despite significant advances in pain research being made by this, and 
subsequent theories, it became obvious that in many cases permanent 
amelioration of pain was not being achieved. In addition, it was observed 
that people responded quite differently to the same pain syndrome and 
reported widely different benefits from the same treatment. Seeing the 
inadequacy of current theories to explain these anomalies Melzack & Wall 
(1965) proposed a new model of pain. The Gate Control Model holds that 
pain intensity is determined by multiple factors. Melzack and his colleagues 
suggested that cognitive-evaluative and motivational-affective factors 
interact with sensory phenomena to produce pain. The conceptual model of 
the gate control theory emphasises the modulation of pain by peripheral as 
well as central nervous system processes and thus provides a physiological 
basis for the role of psychological processes in chronic pain (Turk & Rudy, 
1992). Although this theory looks at the systems that influence the processing 
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of nociceptive stimulation it cannot account for chronic pain occurring in the 
absence of tissue dam.age or other "organic" pathology. 
In response to this criticism., Fordyce developed the operant 
conditioning model (Fordyce, 1976). Fordyce distinguished between 
respondant pain, which is pain resulting from. stimuli arising from. body 
dam.age, and operant pain, which m.ay or m.ay not be associated with actual 
body dam.age. As pain is not directly observable, all that can be known about 
the pain is based on com.m.unications from. the individual which can be 
verbal or nonverbal. These com.m.unications of pain are observable, 
behavioural manifestations and, as such, are subject to the principles of 
operant conditioning. Positive reinforcers, such as solicitous responses from. 
a spouse or family m.em.ber, m.ay serve to maintain the pain behaviours even 
in the absence of nociception. Fordyce emphasised that the overt 
manifestations of pain and suffering (pain behaviours), rather than pain per 
se, should be the target of treatment interventions. 
Although the gate control model and the operant conditioning model 
differ in their views of pain1 they m.ay actually be complementary (Turk & 
Rudy, 1986). Turk, Meichenbaum. & Genest (1983) developed a cognitive-
behavioural model in which people with chronic pain are viewed as active 
processors of information. The cognitive-behavioural perspective suggests 
that behaviour and emotions are influenced by interpretations of events, 
rather than only by characteristics of the event itself. 
According to this m.odet it is the individual's perspective that interacts 
reciprocally with emotional factors, sensory phenomena, and behavioural 
responses. Pain perception is a dynamic, interpretative process. Moreover, 
the individual's behaviour will elicit responses from. significant others that 
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can reinforce both adaptive and maladaptive modes of thinking, feeling and 
behaving (Turk & Rudy, 1986). The cognitive-behavioural perspective 
integrates Fordyce's emphasis on external reinforcement contingencies and 
the respondent view of learned fear and avoidance within the framework of 
an information processing perspective (Turk & Rudy, 1992). 
In order to facilitate adaptive coping in people with chronic pain, this 
approach has developed interventions that attempt to: (a) alter dysfunctional 
cognitions, such as perceived lack of self-efficacy to control pain, distortion in 
the interpretation of pain-related events, somatic preoccupation and 
catastrophising; (b) enhance the individuals use of specific coping strategies; 
and (c) enhance the individuals confidence in their ability to cope (Turk & 
Rudy, 1992). 
Today pain is thought of as a complex psychobiological phenomenon 
influenced by psychosocial factors rather than simply a sensory experience 
arising directly from stimulation of pain receptors (Bandura, O'Leary, Taylor, 
Gauthier & Gossard, 1987). The effects of chronic pain depend on: (a) the 
cause/mechanisms, duration, intensity, and quality of the pain; (b) the genetic 
make up, personality, mentation, attitude, mood, and other psychologic 
characteristics of the individual; and (c) a variety of sociologic factors 
including interaction with the family and persons in the work place, the 
culture/ ethnicity of the individual and the financial impact of the pain 
problem (Bonica, 1990b). Despite advances in pain theories, many people still 
consider pain to be caused by physiological or psychological factors rather than 
acknowledging the interrelationship of these factors. 
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Psychological Influences on Chronic Pain 
Recent models and treatments for pain have emphasised the important 
contribution cognitive factors play in the experience of chronic pain. A 
number of studies have shown that the level of dysfunction experienced by 
people with chronic pain is associated more with psychological variables than 
pathophysiology (See Kleinke, 1992; Turk & Rudy, 1986; Turk & Rudy, 1992). 
From the behavioural perspective, many of the problems associated 
with chronic pain are due to the effects of learning, regardless of the original 
cause of the pain (Keefe, Gil & Rose, 1986). For example, pain behaviours, 
such as resting, may be reinforced by the solicitous responses of a concerned 
spouse or family member (Fordyce, 1976). This can lead to muscle wasting 
and higher levels of pain if activity is attempted, thus confirming the 
individual's 'sick role'. Other studies have demonstrated a close link between 
levels of distress and disability and the individuaYs beliefs and cognitions 
about pain (Crisson & Keefe, 1988). 
People who experience pain develop ways to reduce, tolerate or 
minimise their pain and distress. These efforts to deal with pain have been 
called coping strategies (Rosenstiel & Keefe, 1983). The individual's attitudes 
towards the efficacy of these coping strategies and their use of them may be 
important factors in determining how individuals adjust to chronic pain. 
Coping strategies can be behavioural (for example going for a walk) or 
cognitive (for example reinterpreting pain sensations) although Kleinke 
(1992) suggests that people with chronic pain are less likely to use cognitive 
coping strategies unless they have been specifically taught them. 
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Coping strategies can also be negative (for example, catastrophising). 
Rosenstiel & Keefe (1983) found that reported frequency of using specific 
coping strategies was predictive of pain, functional status and psychological 
distress above and beyond what may be predicted on the basis of patient 
history variables. Fernandez & Turk (1989), in a meta-analysis of the utility of 
cognitive coping strategies, found that "cognitive strategies, when [compared] 
to no-treatment or positive expectancy alone, reduce pain significantly, and 
this effect is a substantive one" (p. 132). The use of 'active' coping strategies, 
such as imagery strategies, is related to lower levels of dysfunction compared 
to the use of 'passive' coping strategies (such as relying on the help of others 
or use of medication). 
As the data suggest that coping plays a role in the individual's 
adjustment to chronic pain, it is important to determine the factors that 
influence coping efforts. The individual's beliefs about their capabilities 
appear to be predictive of their behaviour (Bandura, 1977). From the 
cognitive-behavioural perspective, the occurrence of coping behaviours is 
conceptualised as being mediated by the individual's beliefs that situational 
demands do not exceed coping resources (Turk & Rudy, 1992). Social learning 
theory (Bandura, 1977) posits that people will engage in coping efforts that 
they believe are within their capabilities and will result in positive 
consequences (Jensen, Turner, & Romano, 1991). 
A study by Dolce, Crocker & Doleys, (1986) suggests that low efficacy 
expectancies can contribute to poor treatment response and relapse. Learned 
helplessness refers to the belief that effective solutions are not available to 
eliminate or reduce the source of stress (Turk & Rudy, 1992). Flor & Turk 
(1988) report that greater feelings of helplessness are significantly correlated 
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with psychological distress and physical disability as well as being predictive 
of reports of pain and the number of physician visits per year. 
In order for an individual to decide if a given situation is 'beyond their 
control' they must rely on past experience. Efficient processing of 
information relies on preconceptions and automatic thoughts that occur 
without conscious awareness. These preconceptions influence what evidence 
is used in making inferences, such as efficacy beliefs or learned helplessness. 
Automatic cognitive distortions can have important emotional and 
behavioural effects. A study by Smith, Follick, Ahern & Adams (1986) found 
that the level of cognitive distortion shown by people with chronic low back 
pain is reliably associated with the degree of disability reported by these 
people. 
Biomedical factors, in a majority of cases, appear to instigate the initial 
report of pain. Over time, however, psychosocial and behavioural factors 
may serve to exacerbate and maintain levels of perceived pain and, 
subsequently, disability (Turk & Rudy, 1992). 
Effects of Chronic Pain 
The effects of chronic pain are influenced by a number of factors and no 
two people are the same. Some people with chronic pain display none of the 
following problems although the current literature suggests a widespread 
belief that all people with chronic pain experience serious physiologic, 
behavioural, and social effects (Bonica, 1990c). Bonica further suggests that 
only 3% of people with chronic pain consult specialists in pain management 
programmes and, because these individuals are typically dysfunctional, this 
leads to a distorted picture of the effects of chronic pain. Crook & Tunks 
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(1985) report that people who attend pain management programmes are not 
representative of people with chronic pain. In actual fact, some people seem 
to 'rise to the challenge' and accept the problems associated with chronic pain 
in a seemingly off-hand manner, while another person with the same 
problem may find chronic pain to be completely overwhelming. What 
follows is a brief summary of some of the common effects of chronic pain. 
[For a review of these factors refer Bonica (1990); Pelz & Merskey (1983); for a 
review of the 'chronic pain syndrome' refer Fordyce, Roberts & Sternbach 
(1985); for a review of the effects of chronic pain from the social work 
perspective, refer Roy (1987)]. 
The average individual can briefly bear, both psychologically and 
physiologically, even the most severe pain, if such pain is prolonged it exerts 
effects which cause mental and physical deterioration (Bonica, 1990b). Sleep 
disturbances are the most common complaint among people with 
continuous chronic pain (Sternbach, 1984). Not only can pain keep people 
awake and disturb their sleeping patterns but it also 'wears people down' 
leading to exhaustion and lack of energy. It can also lead to feelings of 
irritability. The individual with chronic pain may also become cynical and 
hostile towards health care professionals, and others, as the pain persists 
despite countless treatments. Changes in eating patterns are also prevalent, 
with some people eating more and others eating less than before the 
development of chronic pain. As mentioned above1 persistent chronic pain 
can also lead to the development of cognitive distortions and feelings of 
helplessness (Turk & Rudy, 1986). 
Many people with chronic pain find they undergo a progressive 
physical deterioration and loss of interest in their old social activities and 
interactions (Bonica, 1990b ). Chronic pain can lead to the individual 
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withdrawing from society, developing problems with friends and family and 
increasingly focusing in on the pain problem. "To summarise the overall 
nature of social problems encountered by many chronic pain sufferers, it 
would seem, that they experience loss of many of the major social roles 
including the occupational ones. In addition, family conflicts are inordinately 
common in this group of patients and sexual difficulties arise with almost 
clockwork regularity. Patients are totally dependent on the health-care system 
and view themselves as victims of the system" (Roy, 1987). Many people also 
display 'pain behaviours' (Fordyce, 1976) such as excessive resting, pain 
complaints, grimacing and limping. The pain can become the centre of the 
individuals life . There can also be financial problems due to an inability to 
work or the cost of seeking treatment. In short, chronic pain can have a 
major impact on almost every aspect of the individual's life. However the 
important point to be considered is that this major impact on the individuals 
life can easily become disproportionate to the actual problem. 
Pain management programmes 
The beginning of multi-disciplinary pain clinics can be traced back to the 
end of World War 2 when Dr. John Bonica realised that many people with 
chronic pain where not being treated successfully. It became apparent that no 
one individual knew enough about the complex problems of chronic pain. 
This lead to the formation of the first pain clinic at the University of 
Washington School of Medicine. The idea of pain clinics has spread rapidly. 
Melzack & Wall (1988) suggest there is at least one pain clinic in every major 
city in the western world. Although each one differs depending on the 
personality and training of the professionals involved, there are certain 
principles that a good pain clinic should take account of. 
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The gate-control theory of pain has provided the conceptual background 
for new approaches to pain management. The theory argues that pain does 
not have a single cause and is not even a single entity. As pain is such a 
complex phenomenon the pharmacological, sensory and psychological 
methods of pain control do not exclude each other and a rational approach to 
pain management requires multiple approaches that converge to produce a 
reduction in suffering (Melzack & Wall, 1988). In multi-disciplinary pain 
clinics an interchange of ideas can occur and the conditions are conducive to 
novel, imaginative approaches. 
One of the primary goals of a multi-disciplinary pain clinic is the 
accurate diagnosis of the individuals' needs in order to recommend 
appropriate strategies for dealing with particular problems. By the time most 
people present at a pain clinic they have already tried a variety of treatments 
to 'cure' their chronic pain problem. Part of the assessment procedure is 
aimed at confirming that all possible treatment options have been exhausted 
and, if this is not the case, referral is made to the appropriate specialist (Loeser 
& Egan, 1989). 
Cognitive-behavioural treatments for chronic pain are rehabilitative by 
nature, aiming at a reduction in the disability, distress and pain behaviours 
associated with the pain rather than 'curing' the pain itself. Generally pain 
management programmes aim to improve the individual's capacity to cope 
with pain, such that a successful client might say "Well, I've still got my pain, 
but it doesn't bother me as much as before" (Nicholas, 1992). 
Most pain management programmes are multi-component 
programmes with each component aimed at addressing a different aspect of 
the person's problems. There is usually a reactivation component consisting 
of various exercise regimes to improve general fitness, muscle strength and 
help with posture. Relaxation techniques are taught to improve the 
management of stress, help with sleep difficulties and reduce muscle tension 
(this may be coupled with biofeedback). Education about chronic pain and its 
management are provided (Philips, 1988) along with cognitive-behavioural 
therapy to identify and modify maladaptive thinking processes and coping 
strategies (Turk, Meichenbaum & Genest, 1983). Occupational therapy may be 
included to help the client with skills training and work options. 
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Throughout the programme operant-behavioural principles (Fordyce, 1976) 
are explicitly employed to help the individual increase their activity level and 
reduce the frequency of pain behaviours (Nicholas, 1992). For a detailed 
examination of the theory and practice of a multi-disciplinary pain centre 
refer Loeser & Egan (1989); Holzman & Turk (1986). 
Research for the present thesis was undertaken at Burwood Hospital in 
Christchurch. The aims of the Burwood MSM pain management programme 
are to decrease levels of distress and increase levels of functioning in people 
with pain that is musculoskeletal in origin. Different programmes have 
different aims depending on the orientation of the programme. For example, 
many overseas programmes are funded by insurance companies with a 
specific interest in seeing individuals with chronic pain return to work. 
Loeser & Egan (1989) report that return to work is one of their most important 
aims (and therefore treatment outcomes). Given the currant employment 
situation in New Zealand, return to work is not a viable alternative for many 
people who attend the Burwood programme. This is because many 
employers would rather hire an able-bodied worker, than someone with 
chronic pain. Considerations about appropriate measures of long-term 
outcome not only indicate the sorts of issues that need to be addressed in 
determining the content of a pain management programme, they also 
demonstrate the limitations of attempts to evaluate these programmes in 
isolation from the context in which they operate (Nicholas, 1992). 
The fact that the Burwood pain centre is based under the 
Musculoskeletal Medicine (MSM) service also distinguishes it from similar 
American programmes. " ... of the 36m patients with chronic pain associated 
with arthritis, gout, and other musculoskeletal disorders, very few have been 
seen in multi-disciplinary or interdisciplinary pain clinics or centres." 
(Bonica, 1990d; p. 190). As the Burwood clinic is run under the 
Musculoskeletal Medicine department, almost all the people that are referred 
to this programme have pain that is musculoskeletal in origin. This point 
has important implications for the consideration of the following section. 
Opioid Therapy 
Halpern & Robinson (1986) have suggested that with the atmosphere of 
experimentation following the development of multi-disciplinary pain 
management programme's the traditional approach of treating chronic pain 
with opioids has been viewed with disapproval. As multi-disciplinary pain 
management programmes are considered 'state of the art' in pain 
management at the moment (Portenoy, 1990) there would appear to be little 
justification for the continuation of opioid therapy. However, many people 
do not have access to this type of programme. 
Christchurch is the only city in New Zealand with a multi-disciplinary 
in-patient pain management centre and this has a six month waiting list. In 
addition, many programmes have high failure and dropout rates (Flor, 
Fydrich & Turk, 1992) while out of those people that do successfully complete 
a pain management programme many do not report any significant decrease 
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in pain severity (Portenoy, 1990). Clinics specialising in the treatment of 
chronic pain consider detoxification from opioids mandatory if chronic pain 
is to be treated and function restored (Halpern & Robinson, 1986). 
One pain management programme that did try using opioids in 
conjunction with multi-disciplinary treatment reports that "During the 
intermittent withdrawal periods [to evaluate physical and psychological 
dependency] pain invariably increased and function decreased. This strongly 
suggests that long-term administration of the narcotic is necessary to 
maintain function in select[ed] patients" (France, Urban & Keefe, 1984). For 
some people in severe chronic pain, opioids may be the only therapy capable 
of alleviating their suffering (Merry, Schug, Richards & Large; 1991). These 
findings would suggest that there is still a place for the use of opioids in the 
management of chronic pain. 
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Although our understanding of chronic pain and its mechanisms has 
changed dramatically in the last 30 years peoples perception of pain has not. 
Since our earliest days people have been trying to alleviate the suffering 
caused by chronic pain. Perhaps the earliest recorded reference to the use of 
opioids comes from the Ebers papyrus ( circa 1550 BC) of Egypt where reference 
is made to the prescription of opium by Isis for Ra's headache (Turk & Genest, 
1979). The term 'opioid' refers to any peptide that binds stereospecifically to 
opioid receptors, regardless of whether it occurs naturally or is chemically 
synthesised (Poole & Jahr, 1992). 
The use of opioids for the control of pain is a misunderstood and 
controversial area which provokes passionate argument on both sides. The 
issues involved relate not only to the perceived advantages and 
disadvantages to the individual opioid user, but also to the impact of opioid 
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regulation and societal attitudes on medical practice. As most of the literature 
on this topic originates in the United States, it is necessary to mention their 
societies' perception of the use of opioids. " ... our [U.S.] history with opioids 
has been marked primarily by problems caused by addiction. This history, 
which goes well back into the last century, has led to an almost hysterical fear 
of opioid drugs among the general public, a strongly repressive attitude 
among drug control and law enforcement officials, and an apprehension 
surrounding even routine use of opioids and an incompetence in prescribing 
and administering them among the health care professions" (Friedman, 
1990; p S 3). 
Even acute pain and chronic cancer pain are under-treated with opioids 
(Melzack, 1988; Portenoy, 1990). Bonica (1980) concludes that moderate to 
severe pain is experienced by 40% of people with intermediate stages of cancer 
and 60-80% of those with advanced cancer. This is despite the fact that the use 
of morphine can virtually abolish pain in 80-90% of cancer patients (Melzack, 
1988). Portenoy (1990) suggests that up to 75% of post operative patients 
report pain of moderate intensity or greater. The under-utilisation of opioids 
not only leads to the 'tragedy of needless pain' (Melzack, 1988) but can actually 
be detrimental to patient recovery and outcome when acute (post operative) 
pain is experienced (Ready, 1990). 
Fear of Addiction 
One of the major causes of the under-utilisation of opioids is what has 
been termed 'opiophobia' (Morgan, 1986). Opiophobia is the under treatment 
of severe pain "based on an irrational and undocumented fear that 
appropriate use will lead patients to become addicts" (p. 163). The primary 
cause of this fear appears to be the confusion of street addicts with people in 
pain (Melzack, 1988). Schug, Merry & Acland (1991) report that experience 
with the clinical use of opioids to treat pain matches neither the experience 
with abusing street addicts nor the results of laboratory experiments in 
animals or pain-free volunteers. Friedman (1990) suggests that the difference 
between drug addicts and pain sufferers is that "while the addict takes his 
drug to get high, "mellow out" and largely avoid life, the pain patient takes 
his drug to get on with life" (p. S4). 
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The fear of creating 'addicts' can lead to a 'self-fulfilling prophesy'. Poor 
knowledge about opioids and fear of addiction may lead to an under 
prescription of opioids which often results in inadequate pain management 
(Morgan, 1986; Portenoy, 1990). This in turn means that the person in pain 
must engage in increasingly desperate attempts to gain pain relief, including 
behavioural changes to convince others of, the pain's severity. The health 
care professional sees these attempts at gaining increased doses as evidence of 
developing dependence on (' addiction' to) opioids and a crises of mistrust 
develops in a vicious cycle with the person in pain displaying more and more 
'evidence of addiction' in an attempt to gain relief from pain. This problem 
has been labelled 'opioid pseudoaddiction' (Weissman & Haddox, 1989) and, 
although the symptoms are the same as those shown by true opioid 
psychologic dependence (' addiction'), develops as a result of inadequate pain 
relief. 
Addiction, in general terms, has been defined as any compulsive 
activity or involvement that decreases the persons ability to deal with other 
aspects of their life to the point where that activity or involvement comprises 
the dominant source of emotional reinforcement and identity for the person 
(Peele, 1977). The sources of addiction lie more in people than in drug actions 
and it is the experience itself that people become addicted to (Peele, 1989). 
Addiction is a word that has only social determinants. It refers to a life in 
which drug use has become paramount (Morgan, 1986). 
Portenoy (1990) has defined addiction, as relevant to the pain patient 
administered opioid drugs, as: 
" .... a psychologic and behavioural syndrome characterised by (a) an 
intense desire for the drug and overwhelming concern about its 
availability (psychologic dependence); (b) evidence of compulsive drug 
use ( characterised for example by unsanctioned dose escalation .. .. . , 
and/or .. .. associated behaviours, including manipulation of the ... 
medical system ... (altering prescriptions for example), acquisition of 
drugs from other ... sources ... , drug hoarding or sales, or unapproved 
use of other drugs ... " (p. 53). 
As this definition is so far removed from the ordinary meaning of addiction 
it would appear to be inappropriate to say that people who have a 
'complicated history of opioid use' are 'addicted'. Such people already face 
challenging problems and the application of such a negative label can only be 
counter-productive to their self-esteem and the treatment they receive. 
Not only does society fail to distinguish between the legitimate and 
illegitimate use of opioids but it is the illegitimate image that dominates 
medical and lay concepts about opioid usage. Messages about the dangers of 
drug abuse appear continually in the media, while drug addicts are portrayed 
as desperate, criminal low-lifes. Invariably, when people with chronic pain 
are thought to be 'addicted' they are classified along with these other types of 
addicts. "The negative biases directed toward street drug users also seem to be 
expressed towards chronic pain patients to whom narcotic analgesics have 
been continuously administered for periods ranging from six months to 
twenty years" (Halpern & Robinson, 1986). 
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Another problem with the use of opioids is the inability of people in 
general, and health care professionals in particular, to understand the 
distinction between physical dependence and addiction (Friedman, 1990; 
Morgan, 1986; Portenoy, 1990; Schug, Merry & Acland, 1991). Physical 
dependence is defined as "the occurrence of withdrawal symptoms after the 
abrupt discontinuation of a drug or the administration of an antagonist" 
(Schug, Zech & Grond, 1992). All humans who are treated with opioids for 
greater than 48 hours will develop physical dependence, manifest by a mild 
and clinically unimportant flu-like syndrome, on abstinence. Unfortunately, 
withdrawal has been regarded as the crucial test of addiction (Peele, 1977) in 
the past and anyone displaying withdrawal symptoms automatically assumed 
to be addicted. 
The occurrence of physical dependence on withdrawal of opioids has 
been likened to 'becoming wet by entering the water' (Morgan, 1986). That is, 
withdrawal symptoms are the natural result of the abrupt cessation of 
opioids. It is the meaning that the individual gives to these symptoms that 
influences their impact and severity. Withdrawal symptoms can be avoided 
completely if the individual is gradually tapered off their opioid medications. 
[Buckley, Sizemore & Charlton (1986) describe in detail the drug withdrawal 
protocol successfully used at the University of Washington Multi-disciplinary 
Pain Centre]. 
Many chronic pain sufferers take their opioid medications on a p.r.n. 
(' as needed') basis. Failure to maintain constant opioid intake elicits 
withdrawal reactions that can trigger increased pain and lead to a vicious cycle 
of increasing doses and increasing pain (Hanson & Gerber, 1990). These 
problems can usually be remedied by appropriate education and effective 
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doses at regular time intervals, or, if necessary, the gradual reduction and 
discontinuation of the opioids. 
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A related issue is the misunderstanding about the effects of tolerance on 
the use of opioids. Tolerance describes the need for increasing doses to 
maintain a defined pharmacodynamic effect such as analgesia (Schug, Zech & 
Grand, 1992) and has traditionally been regarded as related to the addictive 
potential of a substance. The misunderstanding regarding the need for 
increasing doses of opioids to adequately manage pain is due to the 'dual 
pharmacology' of opioids (McQuay, 1989). There is a marked difference in the 
response of pain-free volunteers and people in pain with respect to the 
development of tolerance with the use of opioids. While pain-free 
volunteers rapidly develop tolerance to opioids, people with chronic pain fail 
to demonstrate any change with time of the minimum effective analgesic 
concentration [for example, with pethidine (Glynn & Mather, 1982)]. A recent 
study by Collin, Poulain, Gauvain-Piquard, Petit, & Pichard-Leandri (1993) 
reports data that strongly suggests " ... that instead of pharmacological 
tolerance, the main factor resulting in increasing oral morphine requirement 
in cancer pain management is pain increase due to disease" (p. 319). 
The Use of Opioids in Chronic Nonmalignant Pain 
There is now general agreement in the literature that opioids should be 
used in cancer & acute pain, even if this is not the case in the 'real world'. 
The main reasons for this agreement is that people with cancer pain are going 
to die anyway and people with acute pain are (by definition) only going to 
receive opioids for a relatively short period of time. However, considerable 
debate remains about their use in chronic nonmalignant pain. Here we are 
presented with a group of people who are going to live for a long time while 
taking opioids. As mentioned above, the main issue of contention is the 
potential for addiction inherent in the use of opioid analgesics. A second 
consideration is the efficacy of opioids for those with chronic pain. In the 
mid-1980's a handful of papers began to appear suggesting that, in some 
selected cases, opioids could be used on a long term basis with few untoward 
consequences. 
Taub (1982) describes 313 people with chronic pain who were treated 
with opioids for up to six years. The specific diagnoses of these individuals is 
not described. Although no systematic assessment of efficacy was conducted, 
no individuals reported uncontrolled, spontaneous pain while in therapy. 
No significant side effects, toxicity or tolerance were observed. Thirteen 
people presented management difficulties including prescription forgery and 
heroin abuse. Although this research reflects the mainly anecdotal nature of 
many studies in this area (Schug et al., 1992), it is the largest survey yet 
published showing that opioids can be used in the management of chronic 
pain. 
As many of these studies have been criticised as being methodologically 
compromised [for example studies by Bouckoms et al. (1992); Maruta, 
Swanson & Finlayson (1979); Portenoy & Foley (1986); Tennant & Delman 
(1983)] they have not been reported in this literature review. For those 
interested in a review of this literature refer Portenoy (1989). Much of the 
criticism levelled at these studies is that many do not report objective 
measures of efficacy. This is partly due to the fact that there is no agreement 
in the literature regarding what the perceived goal of long term opioid 
therapy should be (Schug et al., 1991). Is a subjective decrease in the level of 
pain experienced sufficient justification for the continuation of opioid 
therapy, or is demonstrable improvement in functioning a prerequisite to 
accepting efficacy? 
2 1 
Another major concern from an examination of the literature is the 
variance in the amount of people that gain no benefit from opioids. 
Portenoy, Foley & Inturrisi (1990) have challenged the concept that certain 
types of pain are less responsive to opioids by redefining opioid 
responsiveness as the degree of analgesia obtained following dose escalation 
to an end-point determined by either analgesia or intolerable and 
unmanageable side effects. It is questionable whether this advice has been 
heeded in many of the reported studies (for example see Bouckoms et al. 
(1992)). What is more, if adequate analgesia is not provided opioid 
pseudoaddiction may occur. 
22 
Several studies have been published that have used 'satisfactory 
methodologies' (Schug, 1992). France, Urban & Keefe (1984) describe 16 
individuals that still required opioid medications after completing the Duke 
University Medical Centre pain management programme. These people 
were followed on a regular basis with frequent physical and psychiatric 
examinations. France and colleagues found no overt long-term side effects or 
indications of drug seeking behaviour in any of these individuals. They 
found that the use of opioids helped to suppress the pain sufficiently to allow 
all subjects to cope with it adequately utilising the other components of the 
pain management programme. The maximum dose for any subject was 
equivalent to 20mg of oral methadone per day. "The effectiveness of this low 
dose may be based on its combination with a tricyclic antidepressant and 
comprehensive pain management programme" (p. 1381). France et al. report 
that not only were the other components of the pain management 
programme partially responsible for the effectiveness of this low dose 
programme, but these other strategies initially helped to identify the lowest 
effective opioid dose needed for a particular individual. 
23 
Sorge, Steffmann, Lehmkuhl & Pichlmayr (1991) present 'good data' 
(Schug, 1992) on 775 weeks of treatment (with an individual duration of 11 to 
145 weeks) for 12 people with intractable rheumatic pain. The authors report 
that they had to stop opioid therapy in two individuals due to side-effects, and 
in one other due to a failure to produce analgesia. The remaining nine 
individuals achieved sufficient pain relief with no severe side effects, abuse, 
dependence or tolerance being noted up to a period of two years. 
Zenz, Strumpf & Willweber-Strumpf (1990) report on 70 people treated 
with opioids over an average of 158 days. In more than 50% of these 
individuals the pain could be effectively controlled by oral opioids. The 
average pain rating on a visual analog scale dropped from 9.7 to 4.8. The 
general performance status ( as measured by the Karnofsky Performance 
Status Scale (Karnofsky, Abelman, Craver & Burchenal, (1948)) increased 
from 63.6% to 74.1 %. They also found that the only significant side effect was 
constipation which can be controlled by additional medication. 
Zenz, Strumpf & Tryba (1992) describe 100 people chronically given 
opioids for treatment of nonmalignant pain. The dose of opioids was 
increased in 13 of these people and decreased in 21. Good pain relief was 
reported by 51 individuals and partial relief by 28. Only 21 people had no 
beneficial effect from opioid therapy. The most common side effects were 
constipation and nausea. The authors report no cases of respiratory 
depression or addiction to opioids although ten people were withdrawn from 
opioids due to 'lack of compliance' (which is not defined). Zenz and 
colleagues found a strong relationship between pain relief and level of 
functioning, suggesting that the use of opioids decreased people's pain to an 
extent that they could carry on with their lives. "Opioid therapy that provides 
adequate pain relief does not reduce patients' performance, because the 
obstacle that the pain represents to them ("pain brake") is no longer the 
central concern of their daily life" (p. 75). 
Although many of these studies have been criticised' as being 
methodologically compromised (Turk & Brody, 1991) they are suggestive that 
opioids can be used successfully in the management of chronic pain. 
Side effects 
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A fundamental consideration in the assessment of the use of opioids for 
chronic pain (besides the problems of 'addiction') is the extent of possible 
adverse effects. The fear of adverse effects are, to a lesser extent, also relevant 
to the under-utilisation of opioids in acute pain, but when opioids are to be 
used on a long-term basis their potential side effects are especially relevant. 
"This under use [ of opioids] in the short and long term setting is heavily 
influenced by the fear of adverse effects" (Schug et al., 1992, p. 201). For 
example, Sizemore (1989) states "Patients who complain of pain of 
nonmalignant origin are at high risk of developing serious side effects and 
toxicity if they continue to rely on narcotics ... " (p. 118). An examination of the 
literature on the adverse effects of long term opioid use would suggest that 
this may not be the case. Zenz (1991) concludes that the only severe side effect 
of opioids, when correctly prescribed in chronic pain therapy, is constipation. 
Schug et al. (1992) report that the most severe mishaps are related to 
their respiratory depressant effects although these effects are predictable and 
reversible with antagonists. There may also be adverse effects on the unborn 
child. Portenoy (1990) reports that the available data neither conclusively 
demonstrate nor exclude a substantial risk of subtle neuropsychologic 
impairment and this is an area where long term studies are needed to 
establish a definite answer. Generally, cognitive impairment is negligible 
when opioids are correctly titrated to relieve pain (Dunlop, 1992) and, as 
proponents of opioids point out, pain itself can produce considerable 
cognitive impairment anyway. If opioids are used inappropriately , they can 
lead to problems such as cognitive impairment (Sizemore, 1989). 
Pain seems to cancel out most of the side effects associated with opioids 
including tolerance (Schug et al., 1992), addiction (when not complicated by 
psychological factors) (Melzack, 1988), cognitive impairment (Bruera, 
MacMillan, Hanson & MacDonald, 1989) and respiratory depression (Zenz, 
1991; Schug et al., 1992). 
Several writers on the subject of the adverse effects of opioids contend 
that side effects and toxicity have probably been overemphasised in the past 
(Schug et al., 1991; Schug et al., 1992; Zenz, 1991). Almost all opioids produce 
adverse reactions, but these are generally manageable and non hazardous 
(Zenz, et al., 1992). (For a detailed examination of the adverse effects of 
systemic opioid analgesics see Schug et al., 1992). 
It would appear that there is a considerable amount of 
misunderstanding and misconceptions about the use of opioid analgesics. 
The available data suggest that there is a subpopulation of chronic pain 
sufferers who may benefit from the use of opioids without undue 
impairment or excessive risk to society (Friedman, 1990; Melzack, 1990; 
Portenoy, 1990; Schug et al., 1991; Walt 1990; Zenz, 1991). Despite the 
mounting evidence available in the literature, opioids are still under used. 
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Why opioids are not used 
Many American pain management programmes consider detoxification 
from sedatives and opiates mandatory if chronic pain is to be treated and 
function restored (Halpern & Robinson, 1986). One possible reason why these 
programmes are so negative towards the use of opioid medications may be 
the behavioural orientation of most of these programmes. Bonica (1990a) 
reports that because of this orientation, these programmes attract people 
mainly with pain due to operant and psychologic mechanisms. The literature 
on the use of opioids does not take account of this fact and tends to talk about 
people in pain as if they were a homogeneous group when in fact published 
data from pain management programmes are not representative of the 
general chronic pain population. Although it is not mentioned in the 
literature, the behavioural orientation of these programmes may be an 
important contributing factor in why pain management programmes 
advocate the discontinuation of opioids. 
In situations where nociception is not the sole source of suffering, 
opioids are ill-advised (Butler & Murphy, 1989; Sizemore, 1989). As chronic 
pain is influenced by psychological and environmental factors as well as 
nociception, other treatment modalities are necessary to deal with 
psychological factors (such as depression) that influence or reinforce the pain 
problem. Related to this issue, pain behaviours may be reinforced by the 
prescription of opioids (Halpern & Robinson, 1986) which can lead to the 
continuation of suffering after the original pain problem has gone. 
Finlayson et al. (1986) report that in many patients an addiction to drugs or 
alcohol is the main factor that sustains illness behaviour. It would appear 
that at least part of this problem may be due to taking opioids on a p.r.n. (as 
required) basis. Berntzen & Gotestam (1987) suggest that the use of a fixed 
interval schedule, as opposed to p.r.n. which reinforces pain behaviours, will 
not lead to the reinforcement of pain behaviours, and may even contribute 
to their extinction. 
Another problem is not that the information on the benefits and 
potential problems of using opioids is not available, but rather, if we think of 
the reluctance to use opioids as 'opiophobia' (Morgan, 1986), phobias are 
notoriously resistant to change. Changing behaviour requires more than just 
transmitting information. It is the habits of more experienced health care 
professionals that are passed on to new staff and the information that is 
taught to these people during their training is replaced by what they actually 
observe on the job. "Under-treatment is, indeed, "proper" behaviour and 
they are not chastised but are rewarded for behaving like their fellows" 
(Morgan, 1986, p. 166). Many doctors are reluctant to prescribe opioids in case 
they face disciplinary action from health authorities or drug control agencies 
(Portenoy, 1990). This problem should be greatly reduced once standard 
guidelines are introduced for the use of opioids. 
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There are of course other reasons why health care professionals are 
reluctant to use opioids. Pain is a subjective symptom that cannot be 
objectively proven or quantified (Weissman & Haddox, 1989). Illicit drug 
seekers are often extraordinarily devious and clever and once a doctor is 
known as a 'soft touch' they will be harassed (Syme & Wong, 1989). These 
two issues can make it difficult for doctors to accept at face value a person's 
complaint of pain. Health professionals may also be reluctant to prescribe 
opioids in case their analgesic effects mask the development of further 
symptoms, postponing correct diagnosis and initiation of proper treatment 
(Verhaag & Ikeda, 1991). These problems can be greatly reduced by a thorough 
medical examination, inspection of previous medical history and close 
liaison with other health professionals. 
The use of opioids may also lead to the abuse of physical limitations. 
Acute pain, which warns the body to protect itself, may be masked by the 
analgesic effects of opioids and lead to possible excessive wear on already 
damaged body structures (Hanson & Gerber, 1990). Hanson & Gerber also 
suggest that reliance on opioids may inhibit the bodies' production of 
endorphins. Bonica (1990a) reports that there are possibly depletions of 
serotonin and endorphins associated with chronic pain anyway. Both these 
factors can cause a decrease in pain tolerance so that even minor injuries can 
provoke major responses. 
Although reports are emerging that suggest that opioid maintenance 
therapy may be beneficial to some treatment resistant people, these 
investigators warn that patients with current or past substance abuse should 
be excluded from this treatment (Portenoy & Foley, 1986; Bouckoms et al., 
1992) . Schug et al. (1991) go further and suggest that "A history of substance 
abuse by the patient, a relative or associate is a (strong) relative 
contraindication" (p. 237). The guidelines for opioid maintenance therapy 
presented by Portenoy (1990) seem to sum up the literature. "Evidence of 
drug hoarding, acquisition of drugs from other physicians, uncontrolled dose 
escalation, or other aberrant behaviours should be followed by tapering and 
discontinuation of opioid maintenance therapy" (p. 58). These guidelines 
have been criticised as being ambiguous (Turk & Brody, 1992). 
The classification of drug hoarding as a sign of dependency is also 
inappropriate. "Virtually any patient who has had symptom control 
medications prescribed repeatedly will begin to demonstrate 'drug seeking 
behaviour' as a protective mechanism to prevent withdrawal" (Sizemore, 
1989, p. 119). More recent reports have presented findings that question the 
guidelines proposed by Portenoy, citing case studies of individuals that meet 
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the above criterion who have been successfully maintained OD opioids 
(Weingarten, 1991) and methadone (Kennedy, & Crowley, 1990). As yet there 
are no empirically derived, consensually accepted criteria for choosing which 
patients should be placed on chronic opioid therapy (Turk & Brody, 1992). 
The report by Weingarten (1991) involved the presentation of two case 
studies of individuals who had previous histories of drug abuse and that 
were now being maintained on oral opioids with no apparent control 
problems. Kennedy & Crowley (1990) present a pilot study of a methadone 
maintenance-type treatment for people with both chronic pain and substance 
abuse. Physicians were asked to refer individuals who were addicted to 
opioids and seemed to be abusing their medication. Four subjects were 
admitted to this study but one dropped out within four weeks after being 
beaten by her husband for attending the clinic. A battery of tests to evaluate 
mood, pain and function were administered before treatment started and 
every three months thereafter for 19-21 months. Treatment consisted of 
changing the current opioid regimen to a daily oral dose of methadone, 
weekly sessions of behaviourally orientated therapy and weekly random 
urine specimens. Kennedy and Crawly report that the urine screens were 
essential to treatment, as Patient C would not admit to drug abuse until after 
the urine results were obtained and the other two subjects felt supported by 
the external control of monitored urines. 
The authors report that the two subjects who were previously 
intravenously abusing opioids ceased their needle use. The three subjects 
who remained in treatment markedly decreased their substance abuse and 
appear to have improved functionally. It is estimated Subject 1 abused drugs 
2.3% of days since beginning the methadone programme (as assessed by urine 
tests) compared to 100% of days in the year before this study started (as 
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estimated by self-report). Subject 2 abused drugs 0.2% of days since starting 
the methadone programme compared to 50% in the year before. Subject 3 
abused drugs 26% of days since starting the methadone programme compared 
to 75% in the year before treatment. 
For the purpose of this study one of the most important reasons cited 
for the discontinuation of opioid maintenance therapy is the negative effects 
of drug dependence on treatment outcomes of pain management 
programmes (eg. Maruta, Swanson & Finlayson, 1979). Halpern & Robinson 
(1986) report that "A literature review shows an amazing paucity of rigorous 
research in chronic pain patients which supports the widely held belief that 
medications contribute to dysfunction in chronic pain thus patients require 
detoxification" (p. 135). 
Despite this, other studies have reported decreases in drug use after 
treatment as constituting favourable outcomes (eg. Newman, Seres, Yospe & 
Garlington, 1979) but it would appear that the Maruta et al. (1979) report is 
one of the few studies to actually investigate the effects of drug dependence 
on treatment outcome. There seem to be several weaknesses inherent in this 
report. The definitions of dependency and abuse used in the study are poor. 
Drug abuse was defined as: 
No medical explanation, as evidenced by objective signs on clinical 
examination or laboratory or radiologic studies, that ordinarily warrants 
the sustained use of the drug; and one of the following: (1) use of 
narcotic medication ... on a daily basis for more than a month; (2) use of 
nonnarcotic pain-related medication .. .. at the maximum recommended 
dose or above on a daily basis for more than a month (3) simultaneous 
use of four or more pain medications on a daily basis for more than a 
month" (p. 242). 
While drug dependency was defined as: 
No medical explanation, as evidenced by objective signs on clinical 
examination or laboratory or radiologic studies, that ordinarily warrants 
the sustained use of the drug; and one of the following: (l)increasing daily 
dose of narcotic for more than a month (ultimately exceeding the 
recommended maximum dose); (2) simultaneous use of two kinds of 
narcotics on a daily basis for more than a month; (3) use of a narcotic on a 
daily basis for more than a month, with a history of narcotic dependency 
in the past; ( 4) increasing daily dose of nonnarcotic drug for more than a 
month (ultimately exceeding twice the recommended maximum dose) 
with clinical evidence of physical dependency (p. 242). 
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'No medical explanation ... ' implies that all pain syndromes should be 
objectively provable by current diagnostic technology. This is not the case, the 
link between pathology and chronic pain can be convoluted (Schug et al., 
1991). For example in 70% of lower back pain it is not possible to find any 
responsible dam.age (Loeser, 1980). In addition, the use of a narcotic for a 
month is not a valid indication of drug abuse and reflects an inadequate 
definition of the meaning of 'addiction'. The authors admit refinement of 
these definitions and further studies are needed (Maruta et al., 1979t but this 
study is still used to justify the detoxification of chronic pain sufferers (eg .. 
Finlayson et al., 1986). It is not surprising that the study failed to discern any 
major differences between 'non abusers' and 'drug abusers'. Maruta et al. 
(1979) do however report that there were significant differences in treatment 
outcome between groups. 
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These differences may be explained by the goals of treatment which are 
reported in a separate paper (Swanson, Swenson, Maruta & McPhee; 1976). At 
referral patients are "emphatically [italics added] presented with the 
following treatment goals .... To live with pain without pain killing 
medications and sedatives .... " (p. 405). Although Swanson and colleagues 
acknowledge that some people found it an obvious threat to relinquish 
control over their medication there was no choice in the matter. This 
decision that must be made between receiving treatment at a pain clinic or 
continuing to take opioid medications could possibly be a major cause of the 
treatment resistance that is reported. 
The fact that many people are 'dependent' on their medication is 
perhaps the best reason why they should be allowed some input into the 
timing of their stabilisation or withdrawal from medication. People should 
be encouraged to withdraw from their medication while being shown more 
appropriate coping strategies rather than before. Turk & Rudy (1990) suggest 
that this insistence on eliminating opioids means that some people may be 
unwilling to consider treatment. Certainly there are good reasons to 
discontinue opioid therapy in a number of cases (for example when there is a 
large psychological component to the pain), but the literature assumes this 
course of action to be mandatory. 
As the situation stands, most pain management programmes advocate 
the discontinuation of opioids, despite the report by France, et al. (1984) which 
suggests that there is a place for opioids as part of a comprehensive treatment 
programme. A new stream of thought in the literature suggests that opioids 
may be used in the management of chronic pain but not when a complicated 
history of opioid use is present. More recently however several authors have 
suggested that even these individuals may be successfully maintained on 
opioids. To find out why this may be the case it is necessary to examine some 
of the current theories from the field of addiction. 
Theories of Addiction 
Brickman et al. (1982) have suggested that there are four basic 
conceptual approaches to understanding addiction. The first is the 'moral 
model', where the person is held responsible for both acquiring and solving 
the problem and the 'addict' is someone who lacks the 'moral fibre' to resist 
temptation. This approach, although having little support in contemporary 
addiction literature, was predominant during the American Prohibition and 
is still evident in many peoples' attitudes towards 'drug addicts'. The second 
approach is the 'enlightenment model'. Here the individual is responsible 
for the development of the problem but is incapable of changing without 
relinquishing personal control to a higher power or collective entity (such as 
Alcoholics Anonymous) to gain 'enlightenment'. 
The third model of addiction developed as a response to the victim 
blaming approach of the first two models and has become known as the 
'medical/ disease model'. Here the victim is not held responsible for 
acquiring or solving the problem but rather, those with addictive behaviours 
are told that they are suffering from a disease, similar to other biological 
disorders. Addictions are seen as being based on an underlying physical 
dependency which is usually thought to be rooted in internal body chemistry 
(such as predisposing genetic influences). This means that the disease process 
is assumed to be latent even before a person tries a certain chemical and that 
it remains active (although temporarily 'in remission') even if the reformed 
addict has not touched an 'addictive substance' in years (Marlatt, 1985). 
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This model has the advantage of acknowledging the victim has a 
diagnosable problem which is not the individual's fault. However, by stating 
that the problem behaviour is a disease, whose symptoms are beyond the 
control of the individual (like sneezing when we have a cold) we are creating 
the expectation that the individual cannot control their behaviour. It is these 
first three theories of addiction that seem implicit in the literature on the use 
of opioids by people with a complicated history of opioid use. Finlayson, 
Maruta, Morse & Martin (1986) suggest that "Given the well-known inability 
of alcoholics and drug addicts to control [my italics] their drug use, it follows 
that abstinence is the most appropriate end point of treatment" (p. 176). 
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The fourth model of addiction is the 'compensatory model'. In this 
model the individual is not thought to be responsible for the acquisition of 
the addictive behaviour, but is capable of 'compensating' for the addiction by 
taking an active, responsible (self-help) role in the change process. People are 
thought to be active agents in, not passive victims of, their addictions (Peele, 
1985). Incorporating the principles of social learning theory, cognitive 
psychology and experimental social psychology, this approach views addictive 
behaviours as over learned maladaptive habit patterns (bad habits). 
Just because the behaviour can be described as a habit does not mean 
that the person can be held responsible for its acquisition, or be capable of 
exercising voluntary control over the behaviour. It does however mean that 
these 'bad habits' can be analysed and modified in the same manner as other 
behaviours. It also means that the process of changing habits involves the 
active participation and responsibHity of the person involved. Central to the 
compensatory model is the notion that addictive behaviour can best be 
understood as learned adaptive or functional behaviour in the context of 
personal and environmental factors (for example, opioid use is motivated by 
the individual's attempt to cope with stress and chronic pain) rather than by 
simple exposure to 'addictive substances' (Marlatt, Baer, Donovan & 
Kivlahan, 1988; Peele, 1985). Peele & Brodsky (1975) contend that any activity 
(for example love) can be addictive if participation in that activity reaches 
such an extent as to be detrimental to the individual or others. (For a more 
detailed examination of the nature and implications of these four models 
refer Marlatt et al. (1988), Brickman et al. (1982)). 
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One of the consequences of this new approach is the idea that through 
the acquisition of new skills and cognitive strategies, habits can be 
transformed into behaviours that are under the regulation of higher mental 
processes involving awareness and responsible decision making (Marlatt, 
1985a). It is possible for the individual to learn how to escape from the 
clutches of a vicious cycle of addiction, regardless of how the habit pattern was 
originally acquired. 
The process of changing a habit pattern involves three separate stages 
(Marlatt, 1985a). The first stage involves the motivation and commitment to 
change. This stage is extremely important as premature commitment to 
change may lead to self-defeating experiences of failure and a reluctance to 
recommit oneself to the change process. According to Marlatt this stage is 
often neglected by people working in the field of addiction. If the individual 
is not completely prepared to change their maladaptive behaviour pattern 
then the treatment is unlikely to work. This is a major problem in pain 
management programmes where the individual is told that to enter the 
programme they must withdraw from opioids. 
The second stage of the habit-change process is the implementation of 
the habit change itself, the act of quitting or the initial application of control 
strategies to moderate the behaviour. The final and most important stage 
(Marlatt, 1985a) of the change process is the maintenance stage. It is once the 
old behaviour has changed that the individual must work the hardest to 
resist the temptations and stresses of life and the pull of powerful old habit 
patterns. It is during this maintenance stage that the individual must look at 
possible lapses to the old behaviour pattern not as failures but as mistakes 
that can provide 'learning experiences' that can be used to develop more 
effective coping strategies for the future. The individual may discover, for 
example, that periods of increased pain (flare-ups) are high risk situations for 
inappropriate opioid usage and, during these periods, practise new coping 
skills that have been learnt. 
There are several fundamental differences between the medical/ disease 
and the compensatory models of addiction that are relevant to the treatment 
of individuals who have a complicated history of opioid use. One difference 
is that in the disease model of addiction the person is thought to be a victim 
of forces beyond their control. In the case of opioid use this means that the 
physical dependence that opioids produce has left the individual helpless to 
do anything about their problem. The essence of the relapse prevention 
model (Marlatt & Gordon, 1985) (which embodies the principles endorsed by 
the compensatory model) is that the individual is capable of self-control and 
can therefore assume responsibility for the process of change. 
The goals of treatment from the disease model perspective can only 
ever be total abstinence as any contact with the addictive substance will 
inevitably lead to a relapse. Marlatt (1985a) suggests that if the individual is 
told they will lose all control if they touch the addictive substance, this is 
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what happens. "The emphasis of the disease model on the dichotomy of 
abstinence and excess (absolute control vs. loss of control) tends to reinforce 
the oscillation of addictive behaviours from one extreme to the other by 
forcing the individual to adopt one or other of these extreme roles" (p. 17). In 
contrast, the self-control model favours a more individualised selection of 
treatment goals ranging from abstinence to controlled or moderate use. For a 
detailed consideration of the role of moderate use in the treatment of 
addictive behaviours refer Marlatt (1985b ). 
The controversy over the ability to moderate addictive behaviours 
began in 1962 when D.L. Davies, a British physician and alcohol researcher, 
published a report that suggested that 7 'alcoholic' participants in a long-term 
alcohol treatment study reported a pattern of normal, or controlled, drinking 
(Davies, 1962). Since this first study, many researchers have replicated these 
results. Refer Marlatt, Larimer, Baer & Quigley (1993) for a review. 
A new goal of treatment in alcohol and other addictions has been 
termed 'harm reduction'. Harm reduction methods are based on the 
assumption that addictive behaviours can be placed along a continuum of 
harmful consequences. The goal of harm reduction techniques is to facilitate 
the movement from greater to lesser harmful effects of drug use (Marlatt, 
Larimer, Baer & Quigley, 1993). 
Addictive behaviours are thought of as 'bad habits' and, in terms of 
frequency of occurrence, presumed to lie along a continuum of use rather 
than being defined in terms of discrete categories. Addictive habits are 
thought of as controllable behaviours and once the individual has accepted 
this and learned appropriate coping strategies, moderate use is an appropriate 
treatment outcome. Individuals can still engage in activities or use 
substances that they have previously been addicted to because they have been 
taught to recognise danger signs of potential relapse and provided with 
alternative behaviours and cognitions [refer Marlatt & Gordon (1985) for a 
general description of lifestyle modification procedures or Nicholas (1992) for 
a more specific consideration of relapse prevention in chronic pain]. Their 
cognitions have also been modified to treat a lapse from moderate use as a 
learning experience. This point is of fundamental importance to the 
treatment of people who have shown a complicated history of opioid use. 
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From an examination of the literature, it would appear that most pain 
theorists who write on the topic of addiction use the disease model and justify 
the tapering and discontinuation of opioids because once the individual has a 
problem with their use of opioids they will invariably be in danger of 
misusing their medication in the future. Based on this assumption, 
abstinence is the only end point of treatment as Finlayson et al. (1986) 
suggest. If, however, individuals can learn the necessary skills to use their 
medication in moderation then their may be a place for the use of opioids for 
people who have shown a complicated history of opioid use, as suggested by 
Weingarten (1991) and Kennedy, Do & Crowley (1990). The disease/medical 
model of addiction cannot explain the fact that some people can control their 
use of such 'powerfully addictive' substances as heroin (refer Zinberg, 1984). 
One important advantage of reconceptualising addiction as a 
controllable behaviour is that treatment for individuals who have been 
inappropriately prescribed opioids in the first place can begin as an attempt to 
stabilise their use of opioids. As mentioned earlier, many people refuse 
treatment in pain management programmes because they fear losing their 
opioids which they view as their only means of managing their pain. Millar, 
Leckman, Delany & Tinkcom (1992) report results from a controlled drinking 
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treatment programme (where the treatment goal is controlled use rather than 
abstinence) which suggests that moderation of drinking may be a pathway to 
abstinence for individuals who might not otherwise enter treatment. If total 
abstinence is rejected and no other options appear available, there is no 
motivation to make any changes to one's drug taking behaviour (Marlatt, 
Larimer, Baer & Quigley, 1993). The implications of this finding are two-fold: 
(1) individuals who might otherwise not attend the programme are willing to 
enter treatment; and (2) once new appropriate coping strategies are taught to 
these individuals (or their actual pain problem is identified) they may find no 
need for the use of opioids. 
Another major difference in the two approaches to addiction is how to 
treat individuals. The treatment procedures used by the disease model 
approach generally attempt to change the basic personal orientation or belief 
system of the 'addict' through a combination of confrontation procedures and 
conversion techniques. Once a required behaviour change has occurred, it is 
then reinforced by conformity pressures from a peer group (such as Narcotics 
Anonymous). In contrast, the self-control approach is a combination of 
behavioural coping skills and cognitive restructuring techniques, including 
cognitive coping skills. Lifestyle intervention procedures are also 
incorporated which are aimed to achieve a better balance between the sources 
of stress and the repertoire of coping responses that are available to the 
individual (Marlatt, 1985b). These are similar sorts of techniques that are 
taught during a cognitive-behavioural pain management programme. 
Nicholas (1992) states that "the basic components of cognitive-behavioural 
pain manage'ment programs can also be seen as contributing to RP" [ relapse 
prevention] (p. 281). 
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Most pain management programmes aim to provide the individual 
with new coping responses to replace the use of opioids and other drugs 
("skills not pills"). These skills, combined with additional relapse prevention 
strategies (e.g., Marlatt & Gordon, 1985), may enable even those individuals 
that show a complicated history of opioid use to stabilise their use of opioids. 
This is in direct contradiction to the traditional view of this area which 
suggests that abstinence is the only viable treatment outcome. 
The ideal self-control programme should replace maladaptive habit 
patterns with alternative behaviours and skills, with an emphasis on 
substitute activities which provide the individual with at least some of the 
reinforcing consequences associated with the old habit pattern (Marlatt, 
1985a). In the case of opioid use, the over-riding reinforcing consequence is 
relief from pain. The new behaviours and skills are such aspects of the pain 
management programme as relaxation training, exercise and alternative 
. coping strategies. 
From this examination of the theories of addiction it would appear that 
cognitive-behavioural treatment procedures for addiction are similar to those 
utilised by pain management programmes and abstinence from the addictive 
substance may not be the only necessary treatment outcome. 
Concluding comments 
In one respect this study is an attempt to re-examine the need to 
discontinue opioid therapy before the individual begins treatment. Halpern 
& Robinson (1986) state that no evidence exists in the literature addressing 
opioid maintenance as one treatment modality in comprehensive pain 
treatment programmes. Certainly there has not been much work done on 
this question. A study by France, Urban & Keefe (1984) indicates " ... that 
narcotic analgesics can be effectively used to provide long-term pain control 
in combination with a comprehensive pain management programme" (p. 
1380). It is therefore surprising that this line of research has not been 
thoroughly investigated. 
This study goes one step beyond looking at the use of opioids for 
chronic nonmalignant pain to look at the efficacy of opioids in conjunction 
with a pain management programme for those individuals who have shown 
a complicated history of opioid use. The basic premise behind this study can 
be summed up by Melzack & Wall (1988) "Every human being has a right to 
freedom from pain to the extent that our knowledge permits health 
professionals to achieve this goal" (p. x). When a small percentage of people 
develop problems with their use of opioids they should not be withdrawn 
from opioids and left to cope on their own. Rather, positive steps should be 
taken to find ways to help these individuals. Positive treatment strategies for 
this challenging population may lead to greater acceptance of opioid therapy 
in nonmalignant pain. 
This study is not an attempt to advocate the indiscriminate use of 
opioid medications but rather to look at what can be done to help people who 
find themselves with co-morbid chronic pain and a complicated history of 
opioid use. Currently this group of people are slipping through the system. 
Drug rehabilitation centres don't want them because they have chronic pain, 
general practitioners don't know what to do with people who persistently 
present demanding strong opioids and the person in pain is caught in the 
middle. 
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Although the use of opioids is not widely accepted in the literature 
there are still a large number of people prescribed these drugs. This is partly 
due to the fact that many doctors do not know what to do with these people. 
They severely tax the doctor's limited time and resources and are not 
infrequently considered 'undesirable' patients (Stimmel, 1983). The easiest 
answer is to make a referral to another consultant or prescribe the requested 
pain medications and get on with treating people that can be cured. 
The fear of compounding a chronic pain problem with an addiction 
may lead to the under-utilisation of opioid medications in the first instance. 
If an addiction is recognised the physician may be reluctant to stop the 
substance use because of uncertainty that the person can be managed 
otherwise (Finlayson et al., 1986). The purpose of this study is to investigate a 
positive approach to the management of these complex health issues and 
provide treatment options for the physician and the chronic pain sufferer. 
The literature on this issue does not give any indication of what to do 
with people who present with a complicated history of opioid use, except 
withdraw them from medication. In many cases this course of action may be 
inappropriate as these people have genuine pain. They are asking to be 
helped, not to be cast aside as junkies who deserve what they get. A group of 
clinicians who have been meeting to discuss these issues resolved to ask the 
Burwood MSM service to try cognitive-behavioural methods of pain 





All the participants in this project must have chronic non-malignant 
pain which is musculoskeletal in origin. 
Experimental Group. 
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The experimental group (which from now on will be referred to as the 
opioid group) in this study must have demonstrated a complicated history of 
opioid use and a willingness to stabilise their medication. Confirmation from 
the individuals' participating in the opioid group that they have a problem 
with their use of opioids and a wish to do something about it was also 
required. 
A complicated history of opioid use was defined a priori as showing 
evidence of two or more of the following: 
-Drug hoarding 
-Acquisition of opioids from other physicians 
-Uncontrolled dose escalation 
-Use of non-prescribed opioids 
-Concern from doctors ( or other health-care professionals) 
-Convictions for drug-related offences 
-Other eg. Previous history of drug or alcohol abuse. 
These criteria are loosely based on guidelines in the management of 
opioid maintenance therapy for nonmalignant pain proposed by Portenoy 
(1990). 
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This information was obtained from a review of the medical records of 
approximately 40 individuals whose names had been collated after a meeting 
of clinicians working in this area. Although initially the subjects were to be 
selected at random, the participants turned out to be self-selecting by virtue of 
the fact that a vast majority of the people on the list could not be contacted or 
were unavailable for personal reasons. Only two people refused to attend the 
programme when contacted. Those that were willing and able to participate 
were given a 11/2 day assessment which is standard procedure for all 
participants in the residential pain management programme. This assessment 
includes a physical assessment by a Physiotherapist, Occupational Therapist 
interview, nursing assessment, psychosocial assessment (by a psychologist and 
a social worker) and a Doctor's assessment. 
All 7 of the people who were finally recruited for this programme were 
males. They had an average age of 35 (S.D.=6.55) and an average pain duration 
of 139 months (S.D.=70.20). According to the IASP site of pain classification 
(International Association for the Study of Pain; 1986) 5 of this group were 
classified as having pain of the 'Lower Back, Lumbar Spine, Sacrum and 
Coccyx' and 2 as having pain of the 'Upper Shoulder and Upper Limbs'. 
Of the seven subjects who participated in this group four freely admitted 
using their medications intravenously . Four of the seven have spent time in 
prison, and six had a history of drug and/ or alcohol abuse. The subject who 
did not have an obvious history of abuse was, according to his medical records, 




All members of the control group in this study were selected from the 
waiting list of people wishing to participate in the Musculoskeletal Medicine 
Pain management programme. In order to participate in this programme 
people must, after a referral from their doctor, undergo a 1 1/2 day assessment 
by the pain management service. The pain management service offers other 
services for those with chronic pain but after the assessment those people who 
it is thought may benefit from it are asked if they would like to participate in a 
three week residential pain management programme. 
As there is a year long waiting list, the control group consisted of the 
individuals who were next on the waiting list. No attempt was made to 
match the two groups by age, sex, pain site or pain duration as it would have 
been unethical to make people wait any longer than necessary before entering 
them into the programme. The only additional requirement for participation 
in the control group used in this study was that the individual must not have 
shown a complicated history of opioid use. 
Eight people from the top of the waiting list were contacted and asked if 
they were still interested in participating in the programme. Unfortunately 
two people dropped out at the last minute for personal reasons after initially 
confirming that they would be attending. The control group therefore 
consisted of 3 males and 3 females with an average age of 40 (S.D.=7.88) and an 
average pain duration of 42 months (S.D.=22.91). According to the IASP site of 
pain classification 5 of the group had pain of the 'Lower Back, Lumbar Spine, 
Sacrum and Coccyx' and one had pain of the 'Lower Limbs'. 
46 
Procedure 
As there is only room for eight people on the pain management 
programme at one time the opioid group went first, followed by the control 
group. All subjects completed a standard 3 week residential pain management 
programme although the subjects in the opioid group finished on a Thursday 
instead of a Friday due to Easter and therefore had one day less. 
Basically the programme is a Cognitive-Behavioural treatment 
programme involving the services of a multi-disciplinary team providing 
education and skills training. Clients participate in a daily schedule including 
occupational therapy, relaxation training, hydrotherapy, lectures and physical 
therapy in an attempt to cope better with chronic pain. For a copy of the 
programme structure refer to Appendix 1. 
At least two weeks prior to starting the programme the participants from 
the opioid group were contacted and informed consent [refer appendix 2] was 
obtained during an interview with the head psychologist from the programme 
and the experimenter. The participants also received instructions on how to 
complete a 'Pain and medication usage diary' that was to be completed every 
day for seven weeks (that is, from 2 weeks before, until 2 weeks after the 
programme was due to finish). At this stage the members of the opioid group 
were also asked to complete the pre-assessment questionnaires (see below). 
This was done on an individual basis at the Burwood Pain Management 
Service. 
On the last day of the three week programme all 7 members of the 
opioid group again completed the questionnaires and an evaluation of the 
programme. At two months follow-up one individual refused to complete 
the questionnaires and one was not able to be contacted. The remaining five 
members of the opioid group again completed the questionnaires and 
evaluation. 
Figure 1: 
Chart review and selection 
of subjects 


















Diagram of Research Procedure 
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As the participants in the control group came from as far as 400 
kilometres away, they were contacted by mail, provided a consent form and 
asked to begin filling out the 'Pain and medication usage diary', with a 
covering letter included explaining what this additional information would be 
used for. The pre-treatment questionnaires were given to this group on the 
first morning of the programme. They also brought along their consent forms 
on that day. Several members of the control group had already rung with 
questions relating to this study and any unresolved issues were dealt with at 
this stage. 
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The control group completed the same programme as the opioid group 
and filled out their post-treatment questionnaires on the last day of the 
programme. Two months after the completion of the programme, the control 
group was invited back to Burwood for a follow up evaluation which is 
standard practice. Two people did not show up but the others again completed 
the questionnaires and evaluation. 
It should be noted that there were several differences between the two 
groups. The opioid group had one day less at the end of the programme (due 
to Easter) and had been doing less strenuous activities prior to completing the 
post-treatment questionnaires which may have affected pain ratings. Another 
way in which the two programmes differed was due to the characteristics of 
the individuals in the two groups. The members of the opioid group were 
generally suspicious of the motives behind their programme and for at least 
the first week were reluctant to participate in set activities, with some 
individuals consistently arriving late, if at all, to the sessions. Although the 
opioid group took longer to accept the programme and then lost a day at the 
end every attempt was made to ensure that the two programmes were as 
similar as possible. 
Design 
This study was a two group pre, post and follow-up design. The between 
factor was group ( opioid vs. control) and the within factor was assessment 
time (pre, post and follow-up). Data were analysed using a repeated measures 
ANOVA with one between and one within factor. The dependent variables 
were scores on the various questionnaires used to assess pain level, mood, 
cognitions etc. The aim of the study was to examine differences within 
participants scores after they had completed the pain management 
programme, and also to look at differences between the results of the opioid 
group and the control group. 
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Due to the atypical nature of the control group, results for the Beck 
Depression Inventory and Multidimensional Pain Inventory were also 
compared to the Burwood database. The Burwood MSM database is comprised 
of 73 people who have previously gone through the pain management 
programme. Measures were taken for the MPI and BDI only. Thirteen 
individuals have been discarded from the results that are presented here due 
to missing values, leaving 60 people. The average age of the people whose 
data are presented is 38 (S.D.=10.3, range=17-55) and their average pain 
duration is 53.1 months (S.D.=49.9, range=3-240). 
Of the 28 males and 32 females whose results are reported, 63% reported 
their primary pain site to be 'Lower Back, Lumbar Spine, Sacrum and Coccyx', 
according to IASP classification, This compares to 71 % (5/7) of the opioid 
group and 83% (5/6) of the control group reporting their primary pain site in 
this region.This comparison was conducted using repeated measures ANOVA 
with the independent variables being group ( opioid group vs control group vs 
database group) and time (pre- vs post-treatment). All analyses were 
performed using StatView (Abacus, 1986). 
Materials 
The instruments chosen to measure the dependent variables in this 
study were selected so as to assess a range of cognitive variables that are 
thought to influence the individual's ability to cope successfully with chronic 
pain. The following instruments were individually administered to each 
subject as pre-test, post-test and follow-up measures. As very little data exist 
related to this area, a broad range of response domains was assessed. 
Beck Depression Inventory (BDI) (Beck, Rush, Shaw, & Emery, 1979) 
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The revised Beck Depression Inventory is a 21-item self report 
instrument used to assess the severity of depression in adults and adolescents. 
Each of the 21 symptoms is represented by four statements representing 
increasing levels of depression. It is part of the standard psychometric 
assessment procedure for the MSM pain management service. The mean 
coefficient alphas for psychiatric patients and college students are both in the 
high .80s. The one week test-retest reliability is also within the .80s for both 
psychiatric and non psychiatric populations (Beck, Steer, & Garbin, 1988). 
Multidimensional Pain Inventory (MPI) (Kerns, Turk & Rudy, 1985), 
The Multidimensional Pain Inventory, which was formerly known as 
the West Haven-Yale Multidimensional Pain Inventory (WHYMPit is a 52 
item inventory for the multi-dimensional assessment of chronic pain. It is 
divided into 3 parts, each containing several subscales. The MPI has been 
developed within the cognitive-behavioural perspective and examines the 
impact of pain on the individual's life (Interference, Support, Pain Severity, 
Self-control and Negative Mood subscalest the responses of 'significant others' 
to the person's communications of pain (Punishing Responses, Solicitous 
Responses and Distracting Responses subscales) and the individual's 
perception of their present activity level (Household Chores, Outdoor Work, 
Activities Away From Home and Social Activities subscales). 
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The test-retest reliability of the subscales are in the .62-.91 range and the 
internal consistency estimates for all scales ranged from .70-.90 (Kerns et al., 
1985). The construct validity of this scale was assessed by comparing scores 
from the MPI with scores from nine well known and established 
questionnaires. These questionnaires included the Present Pain Intensity and 
the Total Pain Rating Index scales from the McGill Pain Questionnaire 
(Melzack, 1975), the Beck Depression Inventory (Beck, Ward, Mendelson, 
Mock & Erbaugh, (1961), the Depression Adjective Checklist (Lubin, 1965), the 
State-Trait Anxiety Inventory-State form (Spielberger, Gorsuch & Lushene, 
1970), the Health Locus of Control (Wallston, Wallston & DeVellis, 1978) and 
the Marital Adjustment Scale (Locke & Wallace, 1959). The correlation matrix 
derived from these measures "suggested converging evidence for the internal 
as well as the external construct validity of the 12 WHYMPI scales" (Kerns et 
al., 1985, p. 354). 
The MPI is routinely administered to all participants in the Burwood 
pain management programme. This gives the MPI the additional advantage 
of a large number of baseline measures which the two groups in this study can 
be compared to. 
The Coping Strategies Questionnaire (CSQ)(Rosenstiel & Keefe, 1983) 
The Coping Strategies Questionnaire contains 50 items answered on a 7 
point Likert scale from "never do that" to "always do that". The questionnaire 
assesses the extent to which people with chronic pain use 6 different cognitive 
coping strategies (Attention divertion, Reinterpreting pain sensations, Coping 
self statements, Ignoring pain sensations, Praying or Hoping and 
Catastrophising) and two behavioural coping strategies (increasing activity 
level and increasing pain behaviour) when they feel pain. The final two 
questions address the effectiveness of the coping strategies used. This 
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questionnaire was included to determine whether there was any change in the 
types of coping strategies used by subjects after completing the programme and 
also to see if there was any difference between the coping strategies used by the 
two different groups. 
Rosenstiel & Keefe (1983) present data from 61 chronic lower back pain 
patients which suggests that the subscales of the Coping Strategies 
Questionnaire have internal reliability (ranging from .71-.85) with one 
exception, the 'Increasing pain behaviours' had an alpha coefficient of only 
r=.28. This subscale was dropped from the revised version of the Coping 
Strategies Questionnaire but has been included in this study as this was the 
available copy. Main & Waddell (1991) found the test-retest correlations 
between subscales to be good, ranging from .75-.91. 
The evaluation of cognitive factors in chronic pain is a relatively new 
endeavour and it is difficult to obtain adequate psychometric data on these 
new scales. Main & Waddell (1991) found a number of psychometric 
weaknesses in current cognitive measures and concluded that the measures of 
choice at the moment are the Coping Strategies Questionnaire and the Pain 
Locus of Control Scale used together. Main & Waddell (1991) were dealing 
exclusively with the assessment of lower back pain subjects and expressed 
some doubts as to whether questionnaires developed with a particular type of 
patient can be applied more widely. As most of the subjects in this study have 
lower back pain or similar problems these two scales were used. 
The Pain Locus of Control Scale (PLoC) (Main, Wood, Spanswick, Roberts & 
Robson, submitted). 
The Pain Locus of Control Scale is a 20 item self report instrument that is 
answered on a 4 point Likert scale from "very true" to "very untrue." The 
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pain control scale examines patients beliefs about how well they feel they can 
control their pain. [Refer Appendix 3.] The pain responsibility scale concerns 
how far patients feel they are responsible for the management of their pain. In 
a comparison of the psychometric properties of various cognitive measures in 
low back pain patients Main & Gordon (1991) suggest that the Pain Locus of 
Control Scale may be of value in following change and predicting response to 
treatment. Unfortunately the Pain Locus of Control Scale has yet to be 
adequately tested and limited data on its psychometric properties are available. 
The test-retest reliability of the subscales was found to be .95 and .67 by Main & 
Gordon (1991). 
Cognitive Error Questionnaire (CEO) (Lefebvre, 1981) 
The Cognitive Error Questionnaire was designed to detect four cognitive 
distortions ( catastrophising, overgeneralisation, personalisation and selective 
abstraction) in people with lower back pain. The questionnaire consists of 48 
individual vignettes followed by cognitions that reflect one of the four 
cognitive errors. For example, "You just spent three hours cleaning out the 
basement. Your spouse, however, doesn't say anything about it. You think to 
yourself. 'S(he) must think I did a really poor job."' Subjects rate how similar 
each cognition is to the thoughts they would have in a similar situation on a 5 
point likert scale which ranges from "exactly how I would think" to "not at all 
like I would think". 
The final CEQ is actually a combination of two separate questionnaires. 
In this revised version half the questions are specifically related to situations 
involving a lower back pain problem, while the other half are more general. 
The lower back pain vignettes are structurally identical to the general 
vignettes but have themes that included a problem, personal limitation or 
interpretation related to an individual with lower back pain. As not everyone 
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in the programme had lower back pain, subjects were instructed to either 
imagine they had back pain or otherwise rephrase each question in their head 
to relate to their own pain problem. For example instead of thinking "your 
back hurts .... " subjects were instructed to interpret the question as "your neck 
hurts ... ". 
Information on the psychometric properties of the combined CEQ is 
rather limited (Main & Waddell, 1991). Lefebvre (1981) reports both (that is, 
the lower back pain and the general) CEQ have high test-retest reliability (.80-
.85), alternate-forms reliability (.76-.82) and internal consistency (.89-.92). It is 
moderately correlated with the similarly developed Depressed-Distorted Scale 
(Hammen & Krantz, 1976) with .53-.60 .concurrent validity. 
Smith, Follick, Ahern & Adams (1986) have reported data suggesting 
that the level of cognitive distortion is reliably associated with the degree of 
disability reported by people with lower back pain. A recent article by Kleinke 
(1992) has suggested that with the promise shown by research into the use of 
cognitive strategies for coping with chronic pain a new scale has to be 
developed and that "researchers will want to include the concepts of cognitive 
skills, helplessness, negative thinking, catastrophizing and cognitive 
distortion." (Kleinke, 1992, p. 683). At present there is no such scale available 
and the Cognitive Error Questionnaire is one of the few tests available that 
looks at cognitive distortion in lower back pain. 
Three week Pain Management Programme Evaluation Questionnaire 
The 'Three week pain management programme evaluation 
questionnaire' [ refer appendix 4] was a series of 8 questions regarding 
participants opinions of the programme and their medication usage. The 
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questions were answered on a 7-point Likert scale, with room available for any 
comments. 
Pain and medication usage diary (PMUD) 
The 'pain and medication usage diary' is a 24 hour self report instrument 
with room provided to record the following: pain severity and mood before 
and after medication taken, type of medication taken, the situation that lead to 
medication being taken and any alternative pain control strategies that were 
used. A copy of the diary is presented in Appendix 5. The PMUD was filled 
out daily from two weeks before the pain management programme started 
until two weeks after the programme finished. 
Clinical Observations 
Each participant in the opioid group was assigned to a staff member of 
the Burwood Hospital pain management programme for future supervision. 
The clinical observations presented in this study were compiled with the 
assistance of these members of the staff. 
Results 
The results section is divided into 4 subsections: 
a) The first section is a presentation of the means, standard deviations 
and significant results, obtained by using repeated measures ANOV A, for 
each of the questionnaires used in this study. 
b) the second section involves a comparison of the results obtained in 
this study with those already obtained by the MSM Pain Management Service 
for the MPI and BDI. 
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c) the third section involves the presentation of the results of the 'Three 
week pain management evaluation questionnaire'. 
d) The final section is a presentation of the clinical observations of the 
seven members of the opioid group along with selected individual change 
scores. 
Means, Standard Deviations and Significant Results for each Questionnaire. 
Before beginning this research the statistical power of this study was 
estimated by using the results of the Burwood Musculoskeletal Pain 
Management Programme pain severity rating before and after treatment 
(sample size of n=57). The mean pain rating decreased from 51.5 to 45.5. 
(S.D.=10) and it was reasonable to expect a similar decrease in our subjects. 
This gave a critical effect size of .51. Using a 5% level of significance and 
assuming we use a one-tailed test (that is we expect the pain levels to decrease) 
the use of 16 subjects gives an 69% probability of obtaining a significant result. 
(Kraemer & Thiemann, 1987). 
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Due to the poor completion rate for many of the follow-up 
questionnaires these data were not included in the analysis below as it 
decreased the statistical power below an acceptable level. For exqmple, from 
Table 4 it can be seen that during follow-up only 3 members of the Opioid 
group and 2 members of the Control group completed the CEQ. Repeated 
measures ANOV As were performed to investigate significant results from the 
data obtained from the pre- and post-treatment questionnaires only. 
The conventional 0.05 level of significance has been chosen for this 
analysis. However, because of the small number of subjects in each group, it 
was thought that some interesting results may have been overlooked. 
Donaldson (1993) has suggested that " .. for many hypotheses, alpha =0.05 is 
unreasonably conservative and unnecessarily compromises power" (p. 12). 
Related to this study, Donaldson further asserts that if a treatment is 
inexpensive and safe, and failure to treat is expensive and hazardous, one 
should accept a higher risk of Type I errors. For these reasons, results that fell 
between .05-0.10 level of significance have also been included in this results 
section. 
The means and standard deviations of the results of all the 
questionnaires used in this study are presented in tables 1-5. The numbers of 
people completing each questionnaire have also been included in brackets. 
Data were analysed using repeated measures ANOV A with the independent 
variables being group (opioid vs control) and time (pre vs post-test). All 
analyses were performed using StatView (Abacus, 1986). 
Beck Depression Inventory (BDI) 
On the BDI there was a main effect for group with the opioid group 
being significantly more depressed than the control group F(l,11)=17.59, p<.01. 
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There was no significant main effect for time (pre vs post-treatment) in 
depression scores, however if the results of Subject 1 (whose BDI scores went 
from 20 at pre-treatment to 40 at post-treatment) are removed from the 
analysis then there is a main effect for time indicating an overall decrease in 
depression between pre- and post-treatment F(l,10)=7.37; p<.05. No significant 
interaction effect was detected. 
Table 1. 
Means and Standard Deviations (S.D.) of Pre-test, Post-test and Follow-up 
Scores for Opioid Group and Controls for the Beck Depression lnventocy: 
Group Pre-test Post-test Follow-up 
Mean+ S.D. Mean+ S.D. Mean+ S.D. 
Opioid 23.2 ± 5.5 17.0 ± 11.1 18.0 ± 4.5 
(7) (7) (5) 
Control 12.6 ± 5.9 8.2 ±5.4 7.2 ± 4.4 
(6) (6) (4) 
Multidimensional Pain Inventory (MPI) 
On the 'Interference' subscale there was a main effect for group with the 
opioid group reporting higher levels of interference than the control group 
F(l,11)=4.66; p<0.10. There was also a main effect for time with both groups 
reporting less interference at post-treatment F(l,11)=4.08; p<0.10. There was no 
significant interaction effect. 
On the 'Support' subscale a main effect was found for time with both 
groups reporting significantly higher levels of support at post-testing 
F(l,11)=5.58; p<.05. No significant main effect was found for group, nor was an 
interaction effect observed. 
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On the 'Pain Severity' subscale there was a main effect for group with the 
opioid group reporting significantly higher levels of pain severity than the 
control group F(l,11)=5.22; p<.05. An interaction effect between the opioid 
group and the controls over time was also observed F(l,11)=4.66; p<0.10. An 
examination of Figure 2 shows that this effect is due to the opioid group 
increasing their reported pain severity, while the control group reported a 
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Comparison of Opioid and Control MPI 'Pain Severity' 
T-Scores at Pre- and Post-treatment 
Opioid 
Control 
On the 'Distracting Responses' subscale there was a main effect for group 
with the opioid group reporting higher levels of distracting responses from 
significant others than the control group F(l,8)=4.71; p<0.10. No significant 
main effect was found for time, nor was an interaction effect observed. 
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On the 'Life Control' subscale a main effect was observed for group with 
the opioid group reporting lower levels of life control than the control group 
F(l,11)=4.44; p<0.10. There was also a main effect for time with both groups 
reporting higher levels of life control at post-treatment F(l,11)=8.64; p<.05. No 
interaction effect was observed. 
There was a main effect for group on the 'Affective Distress' subscale 
with the opioid group reporting significantly higher levels of affective distress 
than the control group F(l,11)=8.67; p<.05. There was also a main effect for 
time with both groups reporting significantly lower scores of affective distress 
at post-treatment F(l,11)=6.55; p<.05. No interaction effect was found. 
On the 'Outdoor Work' subscale a main effect was found for time with 
both groups reporting a significant increase in outdoor work at post-treatment 
F(l,11)=7.65; p<.05. No main effect was found for group, nor was an 
interaction effect found. 
No significant differences were obtained from. the 'Activities Away From. 
Home', the 'Solicitous Responses', the 'Punishing Responses', the Household 
Chores', the 'Social Activities' or the General Activity Level' subscales. 
Table 2 
Means and Standard Deviations (S.D.) of Pre-test, Post-test and Follow-up t-
scores for Opioid Group and Controls for the Multidimensional Pain 
Inventory 
Subscale Pre-test Post-test Follow-up 
Mean+ S.D. Mean+ S.D. Mean+ S.D. 
Pain Opioid 47.74 ± 12.20 52.32 ± 11.94 48.2 ± 8.67 
Severity (7) (7) (5) 
Control 42.84 ± 8.34 34.82 ± 6.62 35.00 ± 14.79 
(6) (6) (4) 
Interference Opioid 50.11 ± 9.23 47.02 ± 14.21 45.60 ±5.77 
(7) (7) (4) 
Control 43.10 ± 7.25 33.87 ± 6.04 29.50 ± 9.33 
(6) (6) (4) 
Life Opioid 44.38 ± 9.52 53.89 ± 11.96 49.00 ± 8.60 
Control (7) (7) (5) 
Control 53.70 ± 10.41 62.84 ± 4.80 55.00 ± 2.31 
(6) (6) (4) 
Affective Opioid 55.28 ± 8.86 45.08 ± 6.55 50.80 ± 12.93 
Distress (7) (7) (5) 
Control 45.49 ± 7.09 39.74 ± 6.55 40.00 ± 8.72 
(6) (6) (4) 
Support Opioid 44.16 ± 14.05 37.64 ± 14.87 42.60 ± 10.62 
(7) (7) (5) 
Control 50.20 ± 8.63 47.71 ± 10.67 47.75 ± 11.09 
(6) (5) (4) 
Punishing Opioid 54.74 ± 11.26 56.18 ± 4.40 56.75 ±4.27 
Responses (6) (6) (4) 
Control 48.76 ± 10.08 47.60 ± 13.53 46.00 ± 9.83 
(6) (5) (4) 
Solicitous Opioid 52.77± 9.35 48.17 ± 11.73 53.5 ± 12.77 
Responses (5) (6) (4) 
Control 50.32 ± 15.99 51.13 ± 10.32 48.50 ± 10.91 
(6) (5) (4) 
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Table 3 (continued) 
Means and Standard Deviations (S.D.) of Pre-test, Post-test and Follow-up t-
scores for Opioid Group and Controls for the Multidimensional Pain 
Inventory 
Pre-test Post-test Follow-up 
Subscale Mean+ S.D. Mean+ S.D. Mean+ S.D. 
Distracting Opioid 50.52 ± 5.79 54.71 ± 11.56 53.50 ± 13.53 
Responses (5) (6) (4) 
Control 43.93 ± 8.39 42.75 ± 7.21 47.00 ± 11.28 
(6) (5) (4) 
Household Opioid, 49.31 ± 11.99 50.43 ± 11.81 50.40 ± 12.84 
Chores (7) (7) (5) 
Control 54.90 ± 10.59 52.30 ± 5.63 59.75 ± 5.69 
(6) (6) (4) 
Outdoor Opioid 49.19 ± 9.96 53.12 ± 11.80 51.80 ± 10.08 
Work (7) (7) (5) 
Control 56.04 ± 12.30 55.46 ± 11.88 57.75 ± 3.86 
(6) (6) (4) 
Activities Opioid 53.81 ± 11.55 54.94 ± 10.44 54.20 ± 11.52 
Away (7) (7) (5) 
From Control 55.47 ± 11.80 59.80 ± 12.33 52.50 ± 12.26 
Home (6) (6) (4) 
Social Opioid 55.52 ± 3.96 57.07 ± 6.89 53.80 ± 8.11 
Activities (7) (7) (5) 
Control 53.90 ± 9.11 53.78 ± 6.99 55.75 ± 9.39 
(6) (6) (4) 
General Opioid 52.34 ± 7.84 55.54 ± 11.26 53.60 ± 13.83 
Activity (7) (7) (5) 
Level Control 57.56 ± 10.08 57.36 ± 6.00 60.00 ± 5.10 
(6) (6) (4) 
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Pain Locus of Control (PLC) 
On the Pain Responsibility subscale there was a main effect for group 
with the control group reporting taking significantly more responsibility for 
the management of their pain than the opioid group F(l,11)=15.32; p<.01. No 
significant main effect was found for time, nor was an interaction effect 
observed. 
On the 'Pain Control' subscale there was a main effect for group with the 
control group reporting having significantly more control over their pain 
than the opioid group F(l,11)=11.927; p<.01. No significant main effect was 
found for time, nor was an interaction effect observed. 
Table 3. 
Means and Standard Deviations (S.D.) of Pre-test, Post-test and Follow-up 
Scores for Opioid Group and Controls for the Pain Locus of Control Scale 
Pre-test Post-test Follow-up 
Subscale Mean+ S.D. Mean+ S.D. Mean+ S.D. 
Opioid 3.29 ± .95 3.29 ± 2.29 3.20 ± 2.17 
Pain (7) (7) (5) 
Respon- Control 7.83 ± 3.06 8.50 ± 3.27 10.50 ± 3.70 
sibiliti (6) (6) (4) 
Opioid 7.14 ± 3.89 10.86 ± 4.60 8.6 ± 5.50 
Pain (7) (7) (5) 
Control 
Control 16.67 ± 5.35 17.00 ± 5.40 11.75 ± 7.00 
(6) (6) (4) 
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Cognitive Error Questionnaire (CEO) 
A significant interaction effect was found between the opioid and control 
group over time for the 'Catastrophisation (general)' subscale F(l,10)=5.55; 











• • Opioid Control 
Comparison of Opioid and Control CEQ 'Catastrophisation' 
(General) Scores at Pre- and Post-treatment 
On the Catastrophisation (lbp) subscale there was a main effect for time 
indicating a decrease in the tendency for both groups to catastrophise at post-
treatment F(l,10)=7.156; p<.05. No significant main effect was found for group, 
nor was an interaction effect observed. 
No significant differences were found from the Personalisation (general) 
sub scale. 
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A significant interaction effect was found between the opioid and control 
group over time for the Personalisation (lbp) subscale F(l,10)=6.524; p<.05. No 
main effects were found for time or group. 
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• • Opioid Control 
Comparison of Opioid and Control CEQ 'Personalisation' 
(lbp) Scores at Pre- and Post-Treatment 
On the 'Selective Abstraction (lbp )' subscale there was a main effect for 
time with both groups showing a significant decrease in the tendency to 
selectively attend to negative aspects of experiences at post-treatment 
F(l,10)=6.528; p<.05. No significant main effect was found for group, nor was 
an interaction effect observed. 
No significant differences were found from the 'Selective Abstraction 
(General)' subscale, or either of the 'Overgeneralisation' subscales. 
Table 4. 
Means and Standard Deviations (S.D.) of Pre-test, Post-test and Follow-up 
Scores for Opioid Group and Controls for the Cognitive Error Questionnaire 
Pre-test Post-test Follow-up 
Subscale Mean+ S.D. Mean+ S.D. Mean+ S.D. 
Opioid 4.57 ± 4.04 6.33 ± 6.02 6.33 ± 3.06 
Catastrophisation (7) (6) (4) 
(g) Control 5.83 ± 2.93 2.83 ± 2.48 1.00 ± 1.41 
(6) (6) (2) 
Opioid 9.43 ± 6.13 7.83 ± 4.62 10.00 ± 6.00 
Catastrophisation (7) (6) (4) 
(lbp) Control 8.50 ± 4.23 4.33 ± 4.13 1.00 ± 1.41 
(6) (6) (2) 
Over- Opioid 4.00 ± 3.37 5.67 ± 5.35 8.00 ± 6.08 
generalisation (7) (6) (3) 
(g) Control 6.50 ± 4.51 3.67 ± 3.72 0.50 ± 0.71 
(6) (6) (2) 
Over- Opioid 11.43 ± 5.16 10.00 ± 5.14 7.33 ± 3.79 
generalisation (7) (6) (3) 
0bp) Control 8.67± 4.84 5.50 ± 4.37 4.00 ± 5.66 
(6) (6) (2) 
Opioid 4.57 ± 3.31 4.83 ±4.75 7.67 ±5.77 
Personalisation (7) (6) (3) 
(g) Control 4.50 ± 2.43 3.17 ± 2.99 1.00 ± 1.41 
(6) (6) (2) 
Opioid 5.71 ± 3.34 8.16 ± 5.42 8.33 ± 3.21 
Personalisation (7) (6) (3) 
(lbp) Control 7.83 ± 2.48 3.00 ± 2.68 1.50 ± 2.12 
(6) (6) (2) 
Selective Opioid 3.43 ± 3.99 7.17 ± 5.71 7.67 ± 5.86 
Abstraction (7) (6) (3) 
(g) Control 5.67 ± 3.50 5.33 ± 4.18 1.50 ± 2.83 
(6) (6) (2) 
Selective Opioid 10.43 ± 4.08 7.00 ±4.38 6.67 ±4.93 
Abstraction (7) (6) (3) 
(lbp) Control 8.17 ± 3.92 5.33 ± 3.20 2.00 ± 2.83 
(6) (6) (2) 
g= general questions lbp= lower back pain questions 
Coping Strategies Questionnaire (CSO) 
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On the 'Reinterpreting Pain Sensations' subscale a main effect was found 
for group with the control group reporting using this coping strategy 
significantly more often than the opioid group F(l,11)=9.13; p<.05. No main 
effect was found for time nor was an interaction effect detected. 
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On the 'Coping Self-Statements' subscale a main effect was found for 
group with the control group reporting using this coping strategy significantly 
more often than the opioid group F(l,11)=9.05; p<.05. A main effect was also 
found for time with both groups reporting using this coping strategy less at 
post- treatment F(l,11)=3.81; p<0.10. No interaction effect was detected. 
A main effect for time was detected on the 'Praying/Hoping' subscale 
with both groups using this strategy less at post-treatment F(l,10)=11.70; 
p<0.10. No main effect was found for group, however an interaction effect 
was found between the opioid and control group over time F(l,10)=4.60; 
p<0.10. Referring to Figure 5, this effect would appear to be due to the control 








Comparison of Opioid and Control CSQ Praying/ 
Hoping at Pre- and Post-Treatment 
• • Opioid Control 
No significant differences were found for the 'Attention Divertion', the 
'Activities when in Pain' or 'Displaying Pain Behaviours' subscales. 
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A main effect for time was found in the 'Catastrophisation' subscale with 
both groups reporting less catastrophising at post-treatment F(l,11)=20.71; 
p<.001. No main effect was found for group but an interaction effect was 
found between the opioid and control group over time F(l,11)=5.84; p<.05. 
Referring to Figure 6, this effect would appear to be due to the control group 
decreasing their catastrophising significantly more than the opioid group. 
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Comparison of Opioid and Control CSQ Catastrophisation 
Scores at Pre- and Post-Treatment 
On the 'Control' subscale there was a main effect for time with both 
groups reporting an increase in their general ability to control pain at post-
treatment F(1)1)=7.54; p<.05. No main effect was found for group nor was an 
interaction effect detected. 
On the 'Decrease Effectiveness' subscale there was a main effect for time 
with both groups reporting an increase in their perceived ability to decrease 
their pain levels at post-treatment F(1)1)=7.171; p<.05. No main effect was 
found for group nor was an interaction effect detected. 
69 
On the 'Ignoring Pain Sensations' subscale a main effect was found for 
group with the control group reporting using this coping strategy more often 
than the opioid group F(l,11)=4.13; p<0.10. No main effect was found for time 
nor was an interaction effect detected. 
70 
Table 5. 
Means and Standard Deviations (S.D.) of Pre-test, Post-test and Follow-up 
Scores for Opioid Group and Controls for the Coping Strategies Questionnaire 
Pre-test Post-test Follow-up 
Subscale Mean+ S.D. Mean+ S.D. Mean+ S.D. 
Opioid 17.57 ± 5.26 19.00 ± 4.20 10.60 ± 7.30 
Attention (7) (7) (5) 
Divertion Control 18.00 ± 11.73 15.83 ± 7.44 13.50 ± 12.40 
(6) (6) (4) 
Reinterpretation Opioid 5.14 ± 3.80 5.14 ± 4.30 6.40 ± 4.04 
of Pain (7) (7) (5) 
Sensations Control 16.50 ± 12.16 14.83 ± 7.05 9.75 ± 13.67 
(6) (6) (4) 
Coping Opioid 19.57 ± 5.94 16.29 ± 4.39 18.80 ± 1.92 
Self- (7) (7) (5) 
Statements Control 27.17 ± 6.85 24.17 ± 4.36 23.50 ± 5.45 
(6) (6) (4) 
Ignoring Opioid 13.43 ± 4.76 12.57 ± 5.19 9.60 ± 7.23 
Pain (7) (7) (5) 
Sensations Control 21.00 ± 9.61 17.00 ± 4.52 20.50 ± 11.12 
(6) (6) (4) 
Opioid 18.71 ± 9.72 16.29 ± 8.92 19.20 ± 4.60 
Praying/ (7) (7) (5) 
Hoping Control 18.00 ± 6.89 9.00 ± 7.78 4.00 ± 3.37 
(5) (5) (4) 
Opioid 24.29 ± 7.06 21.00 ± 8.12 22.20 ± 8.29 
Catastrophisation (7) (7) (5) 
Control 23.67 ± 2.58 13.50 ± 4.76 8.25 ± 3.30 
(6) (6) (4) 
Activities Opioid 21.14 ± 6.99 20.29 ± 4.89 18.40 ± 3.71 
when in Pain (7) (7) (5) 
Control 16.83 ± 10.85 18.33 ± 8.26 15.75 ± 5.44 
(6) (6) (4) 
Displaying Opioid 26.71 ±4.11 26.71 ± 4.11 23.00 ± 3.54 
Pain (7) (7) (5) 
Behaviours Control 21.00 ± 6.78 20.33 ± 3.14 19.75 ± 4.03 
(6) (6) (4) 
Opioid 2.28 ± 1.60 3.00 ± 1.63 2.2 ± 1.64 
Control (7) (7) (5) 
Pain Control 2.83 ± 0.48 4.33± 0.87 4.25 ± 0.50 
(6) (6) (4) 
Opioid 1.57 ± 1.40 3.00 ± 1.16 2.00 ± 1.00 
Decrease (7) (7) (5) 
Effectiveness Control 2.67± 0.82 3.50 ± 1.05 2.75 ± 2.06 
(6) (6) (4) 
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Comparison of Database with Opioid and Control Groups 
The comparison of the Opioid and Control groups with the MSM 
database was conducted using repeated measures ANOV A with the 
independent variables being group ( opioid group vs control group vs database 
group) and time (pre- vs post-treatment). All analyses were performed using 
StatView (Abacus, 1986). Post hoc statistical tests were conducted on the data 
to determine which groups were significantly different from each other when 
a main effect for group was discovered. The Tukey hsd (honestly significant 
difference) was used as it is a fairly conservative test, and therefore less likely 
to yield a statistically significant result (see eg. Keppel, 1982). This analysis was 
conducted using CLR ANOV A (Clear Lake Research, 1985). 
Beck Depression Inventory (BDI) Results 
An analysis of the Beck Depression Inventory (BDI) results found a main 
effect for group F(2,34)=6.61; p<.01. A post hoc Tukey test revealed that the 
opioid group was significantly more depressed than the control group at pre-
treatment (p<.05). A main effect was also found for time with all groups 
reporting a decrease in BDI scores at post-treatment F(l,34)=15.61; p<.001. No 
interaction effect was detected. [Only 24 of the 60 members of the database 
comparison group had completed the BDI at pre- and post-treatment]. 
Multidimensional Pain Inventory (MPI) Results 
On the MPI 'Pain Severity' subscale a main effect was found for group 
F(2,70)=7.36; p<.01. A post hoc Tukey test revealed that the control group 
reported significantly less pain severity than the opioid group (p<.01) and the 
comparison group (p<.01). An interaction effect was also found F(2,70)=3.08; 










Comparison of MPI 'Pain Severity' T-scores for Opioid, 
Control and Comparison Groups at Pre- and Post-Treatment 
On the MPI 'Interference' subscale a main effect was found for group 
F(2,70)=8.64; p<.001. A post hoc Tukey test revealed that the control group 
showed significantly less interference than the opioid group (p<.01) and the 
comparison group (p<.01). A main effect was also detected for time with all 
groups showing a decrease in perceived interference at post-treatment 
F(l,70)=18.54; p<.0001. No interaction effect was detected. 
On the 'Life Control' subscale a main effect was found for group F(2,70)= 
3.64; p<.05. A post hoc Tukey test revealed that the control group showed 
significantly higher levels of life control than the opioid group (p<.05). A 
main effect was also found for time with all groups reporting a significant 
increase in perceived life control at post-treatment F(l,70)=33.49; p<.0001. No 
significant interaction effect was detected. 
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On the 'Affective Distress' subscale a significant effect was found for time 
with all groups reporting a significant decrease in perceived distress at post-
treatment F(l,70)=34.08; p<.0001. No significant main effect was found for 
group nor was an interaction effect detected. 
On the 'Support' subscale a significant effect was found for time with all 
groups reporting a significant decrease in perceived support at post-treatment 
F(l,70)=4.09; p<.05. No significant main effect was found for group nor was an 
interaction effect detected. 
On the 'Punishing Responses' subscale a significant effect was found for 
time with the opioid and comparison groups reporting a significant increase 
in perceived punishing responses at post-treatment F(l,67)=8.79; p<.01. No 
significant main effect was found for group nor was an interaction effect 
detected. 
On the 'Solicitous Responses' subscale a significant effect was found for 
time with all groups reporting a significant decrease in perceived solicitous 
responses at post-treatment F(l,67)=4.78; p<.05. No significant main effect was 
found for group nor was an interaction effect detected. 
On the 'Distracting Responses' subscale a main effect was found for 
group F(2,67)=3.20; p<.05. A post hoc Tukey test revealed that the opioid 
group reported significantly higher levels of distracting responses from 
significant others than the control group (p<.05). No significant main effect 
was found for time nor was an interaction effect detected. 
No significant differences were obtained from the 'Household Chores' 
subscale. 
On the 'Outdoor Work' subscale a significant effect was found for time 
with the opioid and comparison groups reporting a significant increase in 
outdoor work at post-treatment F(l,70)=11.51; p<.01. No significant main 
effect was found for group nor was an interaction effect detected. 
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On the 'Activities Away From Home' subscale a main effect was found 
for group F(2,70)=9.45; p<.001. A post hoc Tukey test revealed that the control 
group reported engaging in significantly more activities away from home than 
the comparison group (p<.01). No significant main effect was found for time 
nor was an interaction effect detected. 
On the 'Social Activities' subscale a significant effect was found for time 
with the opioid and comparison groups reporting a significant increase in 
social activities at post-treatment F(l,70)=19.14; p<.0001. No significant main 
effect was found for group nor was an interaction effect detected. 
On the 'General Activity Level' subscale a significant effect was found for 
time with the opioid and comparison groups reporting a significant increase 
in general activity levels at post-treatment F(l,70)=17.31; p<.0001. No 
significant main effect was found for group nor was an interaction effect 
detected. 
PMP Evaluation Questionnaire Results 
A summary of the Evaluation Questionnaire results are presented in 
Table 6, with the numbers of people completing each questionnaire in 
brackets. Analysis using an unpaired two-tailed t-test showed there were no 
significant differences between the ratings given by the opioid group or the 
control group for any of the evaluation questionnaires. 
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Table 6 
Mean+ S.D. Answers to PMP Evaluation Questionnaire 
Question No. Grou,12 Post-treatment Follow-u,12 
How useful was Opioid 6.00 ± 1.29 5.00 ± 1.73 
the programme? (7) (3) 
l=no use Control 5.83 ± 1.47 6.25 ± .96 
7=very useful (6) (4) 
Did programme Opioid 5.29 ± 1.70 4.33 ± 2.51 
provide useable (7) (3) 
skills? 
l=no Control 5.83 ± 1.17 4.75 ± 1.50 
7=yes (6) (4) 
Reli less on Opioid 3.86 ± .69 4.00 ± 1.00 
medication? (7) (3) 
l=rely less Control 3.00 ± 1.41 3.00 ± 1.73 
7=rely more (6) (4) 
Stabilise Opioid 3.71 ± .95 3.00 ± 1.73 
medication? (7) (3) 
l=very confident Control 3.17 ± 1.72 2.33 ± 1.53 
7=not confident (6) (4) 
Continue using Opioid 3.57 ± 1.90 2.67 ± 1.53 
new skills? (7) (3) 
l=very confident Control 2.82 ± 2.32 2.50 ± 1.00 
7=not confident (6) (4) 
Would iou Opioid 6.43 ± .53 7.00 ± 0.00 
recommend this (7) (3) 
programme? Control 6.83 ± 0.41 6.75 ± 0.50 
l=no (6) (4) 
7=yes 
Do ~ou feel better Opioid 6.43 ± 0.79 6.33 ± 0.57 
about ~ourself? (7) (3) 
l=no Control 6.33 ±0.82 5.75 ± 1.26 
7=very much so (6) (4) 
Individual Results 
This section involves the presentation of individual case descriptions 
for the opioid group only. 
Subject 1 
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A strong case was presented by the head psychologist at the MSM pain 
management programme to exclude the results of subject 1 from this analysis. 
The main reason for this is because this subject was not a very good candidate 
for a cognitive-behavioural treatment programme. This subject was of below 
average intelligence (as measured by the WAIS-R (Wechsler, 1981) which was 
administered before the subject entered the programme) and unable to 
comprehend much of the theoretical component of the programme. Related 
to this factor, the subject was expecting a 'miracle cure' from his involvement 
and no amount of explaining the nature of the programme could deflate his 
unrealistic expectations of his participation in this programme. Main & 
Parker (1989) state that "Patients may be considered unsuitable for 
treatment.. .. because they are still seeking a 'miracle cure' and are not prepared 
to consider a self-help approach." (p. 141). From the results of Subject l's 
questionnaires and follow-up evaluations by clinic staff it is clear that he is 
still struggling to come to terms with his situation. There are however other 
people in the same situation and by including his results in this analysis it is 
hoped that something may be added to the understanding of what can be done 
for such people. 
Subject 1 was perhaps the most severely disabled individual in the 
opioid group and many of his fellow group members expressed surprise and 
admiration at how well this subject copes with such severe injuries and pain. 
Consultation with staff that have been involved in following up this subject 
have confirmed that he has made little or no gains since the programme. 
Subject 2 
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This subject was very suspicious of the motives behind the programme 
from the outset. During the first 8-10 days he was cynical and withdrawn, 
threatening on several occasions to drop out of the programme. By the end of 
the programme this individual had stabilised his medication although in 
answer to the question 'How confident are you that you will be able to 
maintain stabilised medication levels' this subject responded slightly 
negatively both at post-treatment and follow-up. Although he had his level of 
opioids increased just prior to the programme his dose has now stabilised and 
he reportedly has stopped using his medication intravenously. This subject 
may be considered at least a partial success, reporting that because of the 
programme he is happier and able to partake in more activities. Six months 
after completing the programme he is still attending an ongoing self-help 
support group for chronic pain, which is based at Burwood, and his 
medication intake remains stable. 
Subject 3 
Subject 3 had actually withdrawn himself from all medication just 
before commencing the pain management programme although he had a 
history of drug and alcohol abuse and the potential to relapse. This subject 
was thought of as conservative by most of the other members of the opioid 
group, and complained at times about the lack of compliance and motivation 
shown by some members. This subject participated fully in all activities and 
gained maximum benefit from his participation. When this subject arrived 
for the programme, he was walking with the aid of a cane which he had 
discarded by the end. Subject 3 has not used opioid medications since the 
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completion of the pain management programme although in answer to the 
question 'How confident are you that you will be able to maintain stabilised 
medication levels' this subject responded slightly negatively both at post-
treatment and follow-up. This suggests that he still experiences a relatively 
low level of self-efficacy. Despite this it would be reasonable to suggest that 
this subject gained significant benefit from the pain management programme. 
Subject 4 
Subject 4 consistently complained that he didn't belong in a group with 
'all these drug addicts'. However, an examination of his file revealed a history 
of alcohol and drug abuse, as well as strong suspicions of current opioid 
misuse. Early on this subject repeatedly threatened to leave the programme 
although he participated fully in all activities along with subject 3. Early on 
this subject appeared to be cynical and lacking in self-esteem. By the end of the 
programme, he was much more positive and looking at working actively as 
an artist on completion of the programme. This subject's long-term outcome 
is unknown as he has not been seen by clinic staff for some months. 
Subject 5 
This subject had been through the pain management programme 
previously and for the first week seemed uninterested in participating. This 
situation was not helped by the fact that he went home at nights rather than 
staying with the group. The other members of the group described him as 
'stand-offish, loudmouthed and negative' and he nearly came to blows with 
another member of the group in the staff cafeteria. By the end of the 
programme he was involving himself more in activities but due to his 
attitude early on could not have obtained maximum benefit from 
participating in the programme. This subject admitted using his medications 
intravenously and claimed that participating in the programme had 'cured 
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him'. In answer to the question 'How confident are you that you will be able 
to maintain stabilised medication levels' this subject responded that he was 
extremely positive this was the case. This subject responded extremely 
positively to all the evaluation questions but at follow-up refused to answer 
any questionnaires, claiming they were all a waste of time. This subject has 
not kept in contact with his follow-up staff member from the programme and 
after consultation with clinic staff it would be reasonable to conclude that he 
gained little or no benefit from his participation in the programme. 
Subject 6 
Subject 6 unobtrusively participated in most but not all of the 
programme. He admitted using his medication intravenously and had 
contracted hepatitis as a result. He had also spent time in prison for drug-
related offences. This subject had a severe dental phobia and needed major 
dental surgery while on the programme. This procedure was cancelled several 
times and interfered with his ability to concentrate on the PMP. This subject 
has not been heard of since the programme and it is strongly suspected that he 
has continued abusing his medication. 
Subject 7 
At the initial interview subject 7 was reluctant to join the programme as 
he wanted to undergo drug detoxification as a priority. He admitted abusing 
his medication intravenously and showed a willingness to seek help, as his 
relationship was suffering as a result of this abuse. During the first week of 
the programme the subject reported that these domestic difficulties resulted in 
a lack of focus and indifference towards the pain management programme 
and other members of the group. This subject often appeared to be cognitively 
impaired by his medication usage and often complained about various aspects 
of the programme and his medication regime. 
This subject had a history of intravenous drug use but had stopped this 
behaviour prior to developing chronic pain. Although he had his level of 
opioids increased during the programme his dose has now stabilised and he 
reportedly has stopped intravenously using his medication. This individual 
has been closely monitored since completing the programme and it would 




Selected Individual Scores for Opioid Group at Pre- Post- and Follow-up 
Measure Subject 
1 6 J i ~ _§. z 
Depression Pre 20 26 30 27 16 17 27 
Scores Post 40 17 4 13 13 14 18 
(BDI) ELm2 23 18 14 22 * * 13 
Pain Pre 4 7 3 7 6 8 15 
Control Post 4 8 7 14 13 13 17 
{PLoC} ELm2 5 9 5 6 * * 18 
Pain Pre 3 3 4 2 3 3 5 
Respon- Post 3 4 0 4 4 1 7 
sibility: ELm2 1 4 1 4 * * 6 
Affective Pre 61 66 56 50 50 61 40 
Distress Post 53 43 53 40 38 40 48 
{MPI} ELm2 69 51 43 56 * * 35 
Pain Pre 61 33 53 49 57 53 29 
Severity Post 69 41 65 37 57 49 49 
(MPI} ELm2 57 45 45 57 * * 37 
Inter- Pre 58 37 62 49 47 58 41 
ference Post 67 35 62 40 30 56 40 
(MPI} ELm2 51 48 38 50 * * 41 
Note: *=subject did not complete questionnaire 
Discussion 
The discussion section is divided into two subsections: 
a) The first section is a summary of the results of the pain management 
programme. 
b) The second section is a discussion of the theoretical and practical 
implications of these results. 
Discussion of Results 
The central hypothesis developed for this study was that contrary to the 
literature, individuals with chronic pain and a complicated history of opioid 
use would gain as much benefit from participating in the MSM pain 
management programme as individuals who have chronic pain and no 
complicated history of opioid use. As the selected control group was atypical 
of the average group, comparisons were made both with that group and with 
the Burwood database results (which included all participants in the 
programme with complete data from February 1991 until February 1992) for 
the BDI and MPI. It would appear from the results obtained from the MPI 
and BDI that the opioid group gained similar benefits from the programme as 
the average participant, as represented by the database results. 
The second hypothesis was that there were cognitive differences 
between the opioid and control groups that would be detected by the CSQ, 
CEQ and the PLoC. Using repeated measures ANOV As, some differences 
were found between these two groups. Of greatest significance is the finding 
that the opioid group appears to be less amenable to changing cognitive 
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distortions and resulting maladaptive cognitive coping strategies (for 
example catastrophising). 
Discussion of Beck Depression Inventory (BDI) Results 
From the results presented, it can be seen that the members of the 
Opioid group were significantly more depressed, on average, than the 
members of the Control group at pre-treatment. This result is probably due 
to the fact that the control group was coping with chronic pain to a greater 
degree than the normal participant in the pain management programme. 
The opioid group was also more depressed than the database average 
although not to a statistically significant degree. 
The opioid group on average scored 23.2 on the BDI while the control 
group scored 12.6 and the database average at pre-treatment was 16.6. Turner 
& Ramano (1984) have suggested that a score of 13 is the threshold for 
signifying the presence of depression in people with chronic pain. This 
would suggest that the average person who attends the pain management 
programme is depressed. High scores on the BDI do not actually mean that 
people are depressed however, as high responses (indicating depression) on 
many of the BDI questions naturally occur with chronic pain. For example, a 
person may report sleeplessness or worry about their health but in actual fact 
this may be perfectly normal behaviour considering their condition. 
There was a main effect for time with all groups reporting a decrease in 
depression levels at post-treatment. This finding reflects a decrease in actual 
self-reported depression by most people completing the pain management 
programme. This is an especially important result as the presence of serious 
depression can seriously complicate treatment (Ward, 1990). The 
psychobiological theory of learned helplessness may provide an explanation 
83 
84 
of these results. This theory predicts that efforts focused on giving the 
individual a sense of mastery over their pain will lead to a decrease in 
depression (Ward, 1990) and feelings of helplessness. This speculation is 
supported by the opioid and control groups both reporting a significant 
increase in their perceived ability to control their pain and decrease their pain 
levels (as measured by the CSQ) at post-treatment. 
From the results presented in Table 7 it can be seen that one member of 
the opioid group reported higher levels of depression at post-treatment than 
at pre-treatment. It is felt however, that this score reflected the subject's 
unrealistic expectations of the programme and his score had decreased to the 
pre-treatment level at follow-up. The high post-treatment score shown by 
Subject 1 can be interpreted as a 'plea for help'. The BDI is used more as a 
screening measure and to facilitate expressions of distress than as an indicator 
of depression. At the Burwood pain clinic, diagnosis of depression is only 
made after an interview with a clinical psychologist. 
From the literature, there are no data to suggest that the use of opioids 
induce depression although they may exacerbate it by increasing fatigue, sleep 
disturbance and hyperphagia while impairing concentration (Ward, 1990). 
Sizemore (1989) has suggested a link between depression and high levels of 
drug use for people with chronic pain because of their effect on mood. 
However, from a review of the literature, it would appear that relatively little 
research has been done on the long-term effects of opioid use on mood for 
people with chronic pain. This is an area that deserves considerable 
attention. A study by Berntzen & Gotestam (1987) found that the use of a 
fixed interval analgesic schedule (as opposed to p.r.n.) was more effective in 
elevating mood in people with chronic pain. This may have been due to the 
accompanying reduction in subjective pain that was also reported. 
Bouckoms et al. (1992) report that, from their clinical findings, the 
absence of depression was an important ingredient for safe opioid use. As 
mentioned in the Introduction, if depression is contributing significantly to 
the chronic pain, opioids are not going to be very effective anyway and may 
lead to more problems. If chronic pain is causing the depression, then 
alleviating the pain by the use of opioids may help considerably reduce the 
depression. 
The nature of the depression experienced by people in chronic pain in 
general, is an area that needs considerable work. While the relation of 
depression to substance dependence and chronic pain remains unresolved 
(Finlayson et al., 1986) these syndromes do seem to overlap and more 
research in this area is needed, especially to assess the role that depression is 
playing in the individual's chronic pain problem. 
Discussion of Multidimensional Pain Inventory (MPI) Results 
The results of the MPI were generally quite positive. On most subscales 
all groups generally showed improvements. 
On the 'Pain Severity' subscale both the control group and the database 
comparison showed a decrease in reported pain severity, while the opioid 
group showed a slight increase. As the opioid group is quite similar to the 
database in most measures of the MPI it is not possible to speculate about 
what factors have lead to the opioid group reporting a higher average level of 
pain severity at post-treatment than at pre-treatment. Although the 
difference is small the trend may indicate that the opioid group on average 
was less responsive to cognitive-behavioural change as the literature 
suggests. 
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Cognitive-behavioural treatment program.mes do not tend to actually 
decrease levels of pain severity as the focus is on coping with chronic pain. 
By the time most participants attend the Burwood pain management 
program.me they have usually tried a large variety of procedures to 'cure' the 
pain problem.. The principal focus in cognitive and behavioural treatments 
for chronic pain is reduction in the disability, distress and pain behaviours 
associated with the pain rather than resolution of the pain itself (Fordyce, 
Roberts & Sternbach, 1985). However, these program.mes should not actually 
increase the level of pain that is reported. Referring to Table 7 it can be seen 
that four out of seven of the opioid group had increases in reported pain 
severity at post-treatment. The difference between the opioid group and the 
database was small and there was no main effect for time evident from. the 
results section which makes any clear interpretation difficult. 
The increase in pain levels m.ay be due to higher pain levels at the time 
the questionnaire was administered, possibly due to high activity levels on 
the day, and during the preceeding three weeks. An important, and often 
neglected, consideration in the examination of these results in general is the 
fact that chronic pain severity (and associated problems) are not stable over 
time. It could be that the subjects were assessed on a 'good' day at pre-
treatment and a 'bad' day at post-treatment. This m.ay however, be an area 
that warrants further investigation. 
All groups showed a decrease in 'Affective Distress' and 'Interference' 
and an increase in 'Life Control', these are all extremely positive results and 
are the focus of the cognitive component of the pain management 
program.me. The program.me aims to put the pain problem. in perspective, 
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that is, to take peoples attention away from the pain problem as the focus of 
their lives. 
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The 'Interference' subscale looks at the perceived impact of chronic pain 
on the individual's life in general. Questions ask if the pain has affected the 
satisfaction gained from, and ability to participate in, certain activities and 
relationships. A major problem for people with chronic pain is the fact that 
they can not do the things they used to be able to do. These feelings of 
interference can become overwhelming and the pain management 
programme aims to assist people to assess their own limitations positively. 
The 'Affective Distress' subscale looks at feelings of irritability, tension 
and overall mood during the past week. Feelings of tension and irritability 
can actually increase pain levels and for this reason relaxation training is part 
of the pain management programme. Another reason for the decrease in 
affective distress is the fact that many participants have previously not had 
contact with other people with chronic pain and being able to talk (and laugh) 
positively with people in similar situations is very beneficial. 
The 'Life Control' subscale looks at the amount of control the 
individual has over their life, and problems, during the last week. The pain 
management programme provides an opportunity for individuals to step out 
of their lives for three weeks and be 'taken care of without the worries of 
their everyday lives impinging. At the same time they are learning about 
what having chronic pain actually means and how to express themselves. 
Many people who attend the pain management programme are not aware of 
what has happened to them or what can be done about it. The programme 
provides information about relevant services that are available (for example 
A.C.C., Social Welfare and the medical system), as well as how to express 
their needs and limitations positively . The programme also tries to increase 
the perceived level of control the individual has over their pain, which is 
usually seen as a major problem area in the individual's life. 
All three groups reported a decrease in perceived 'Support' at post-
treatment. Although it may seem intuitively that the programme should 
increase levels of support this is not the case. The pain management 
programme aims to improve the individual's self-efficacy and feelings of 
being in charge of their own life. The support subscale looks at such aspects 
as the perceived attentiveness and support of a significant other to the pain 
problem and it may be that the perceived decrease is actually due to 
individuals realising that they do not need as much support as they 
previously thought. The fact that the control group (who are functioning 
better judging by all other subscales) reported significantly less 'Distracting 
Responses' than the opioid group tends to support this theory. 
Related to this issue, all three groups also reported a decrease in 
solicitous responses, which are such things as the significant other taking 
over chores and getHng the individual to rest when in pain. All three groups 
also reported an increase in punishing responses which include such items as 
the significant other expressing irritation, frustration or anger at the person 
with chronic pain. It is difficult to speculate why the participants in the pain 
management programme perceive that their significant others have 
increased their punishing responses after they have completed the 
programme. Generally, a decrease in punishing responses would be expected 




Although an important aspect of the behavioural model of chronic 
pain (Fordyce, 1976) the education of significant others about appropriate 
responses to pain behaviours is not an aspect of chronic pain that receives a 
great deal of attention at the Burwood pain management programme. This is 
due to a number of factors including the difficulty of involving significant 
others in the programme and time constraints of the programme itself. 
However, if relationship difficulties are thought to be having a significant 
impact on the individual's life, additional therapy may be included. One of 
the members of the opioid group, along with his partner, received extra 
counselling before and after the programme. 
It is therefore somewhat surprising to see significant main effects for 
time appear for the 'Punishing Responses' and Solicitous Responses' 
subscales although the direction of change is positive for the 'Solicitous 
Response' subscale. Fordyce (1976) has suggested that people with chronic 
pain may be reinforced for 'pain behaviours' (for example, receiving 
sympathy for lying down when in pain) which leads to a continuation of 
these negative responses to pain. A decrease in solicitous responses and an 
increase in punishing responses may be due to changes in attitudes of the 
individual who has completed the Burwood pain management programme 
rather than any changes in the behaviour of their significant other. 
Although in the case of the decrease in solicitous responses, perhaps the 
three weeks that the 'significant other' has without the person with pain 
being around has given them time to realise they had been too solicitous in 
the past. 
Both the opioid and database groups reported an increase in outdoor 
work, social activities and general activity level. These results are consistent 
with the aims of the Burwood pain management programme which 
encourages the reactivation of the person with chronic pain. Physical 
deactivation, which is often associated with chronic pain, leads to weakening 
and shortening of muscles, ligaments and other soft tissues, which when 
provoked by activity, produces more pain (Butler & Murphy, 1989). 
During the programme several members of the opioid group reported 
that it was the first time they had been able to 'play' for years. These positive 
increases in activity level may in part be due to the education sessions aimed 
at increasing activity levels and also the extensive use of the Burwood 
hydrotherapy pool during the program.me. The use of this pool is a gentle 
(and enjoyable) way for a person with chronic pain to begin the process of 
reactivation. The control group did not report any increase on these 
subscales, possibly due to the fact that the members of this group were already 
functioning well at pre-treatment. 
No significant increases were reported in 'household chores' or 'activities 
away from home' subscales. 
Comparison of Opioid Group with MSM Database 
Generally, the opioid group reported similar scores on the MPI 
subscales as the larger database comparison. This suggests that the members 
of the opioid group are more similar to the average participant in the pain 
management programme, as measured by the MPI, than to the members of 
the selected control group. The fact that there were no significant differences 
between the opioid group and the database on any of these measures is rather 
surprising. Spanswick & Main (1989) suggest that there is a close relation 
between high levels of narcotic consumption and levels of distress which 
means that the opioid group may have been predicted to show higher scores 
on the 'Affective Distress' subscale. However, the 'Affective Distress' subscale 
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measures levels of irritability and overall mood during the past week rather 
than actual distress. The fact that the opioid group showed similar scores on 
this subscale indicates that their use of opioids has not had an effect on their 
reported mood. 
These results would suggest that whatever factors contribute to people 
developing a complicated history of opioid use may not be measured by the 
MPI. It is possible that other factors are responsible for the development of 
complications with the use of opioids. Future research might be better 
directed towards some of the factors that are postulated by researchers in the 
field of addiction (eg. Peele, 1989; Marlatt & Gordon, 1985). It would also 
appear that the MPI is insensitive to the distinctions between individuals 
with a complicated history of opioid use and the average participant in the 
programme. 
It is also interesting that the members of the opioid group did not 
report higher scores on the 'Pain Severity' subscale than the average 
participant. This would suggest that it is not just the level of pain that is 
experienced that is responsible for the initiation of, and subsequent 
complications with, the use of opioids (Spanswick & Main, 1989). However 
several investigators have questioned the reliability of simple visual analog 
scales for the assessment of chronic pain (eg. Carlsson, 1983). 
Comparison of Control Group with MSM Database 
From the MPI results it can be seen that the control group reported 
significantly lower levels of 'Pain Severity', 'Interference' and 'Distracting 
Responses', and higher levels of 'Activities Away From Home' (they also 
showed non-significantly higher levels of life control) than the average 
participant in the MSM pain management programme. This would suggest 
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that the members of the control group were coping with chronic pain better 
than the average person who participates in the pain management 
programme. This finding is supported by the comments of the staff at the 
Burwood pain management programme, who reported that the control 
group use in this study was atypical. 
Cognitive differences between the Opioid and Control groups 
According to Turk & Rudy (1992) there are at least three components to 
the cognitive aspects of chronic pain. The first construct has been labelled 
cognitive schema. These are general beliefs, appraisals and expectations 
about pain and are generally related to feelings of self-efficacy. The Pain 
Locus of Control Scale has been used to assess this construct. The second 
construct has been labelled cognitive processes, these are mental processes 
involved in pain control attempts. Cognitive processes are responsible for 
the transformation of new information and the modification of internal 
representations. The Cognitive Error Questionnaire has been used to assess 
this construct. The third construct is cognitive content. Cognitive content 
incorporates the specific cognitive content about the individuals situation 
and their attempts to cope with pain. The Coping Strategies Questionnaire 
has been used for the assessment of this construct. Although these constructs 
are interrelated no single scale adequately evaluates the role of cognitions in 
chronic pain. 
Discussion of Pain Locus of Control (PLC) Results 
The PLC was included in this study as a means of evaluating how 
much control the individuals thought they had over their pain. Feelings of 
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self-efficacy are a central construct in the cognitive-behavioural model of 
chronic pain (Turk & Rudy, 1992). 
The PLC results show that there was a significant difference between 
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the opioid and control groups. The control group reported taking 
significantly more responsibility for the management of pain and also having 
more control over their pain than the opioid group. Unfortunately little 
work has been done on the role of locus of control in influencing chronic 
pain behaviour. A study by Crisson & Keefe (1988) reports that subjects who 
rated their ability to control and decrease pain as poor exhibited more 
psychological distress and reported more depressive, anxiety and obsessive-
compulsive symptoms. 
Stated in its most general terms, Marlatt & Gordon's (1985) conceptual 
model of relapse prevention states that an effective treatment results in 
enhanced perception of control (high self-efficacy) over important events that 
are likely to reinstate problem behaviour (Wilson, 1992). This implies that 
the individual's pain locus of control may be a crucial determinant from the 
perspective of successful pain management treatment and the ability to 
stabilise the use of opioids, and prevent relapse. 
This could mean that locus of control may be a significant determinant 
of the ability to use opioids appropriately. Spanswick & Main (1989) suggest 
that people who feel that they bear little responsibility for how pain affects 
them also tend to have a higher consumption of narcotics. These people do 
not feel that they can gain any control over their pain and in particular rely 
on others to help their pain. The concept of learned helplessness is related to 
an external locus of control where the individual feels helpless to do 
anything about their pain problems. The lower control scores shown by the 
opioid group may be as a result of years of dealing with chronic pain and 
opioid use or it may reflect a premorbid disposition. Peele (1989) has 
suggested that 'addicts', as a group, feel more powerless and out of control 
than other people even before becoming addicted. 
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Due to the atypical nature of the control group it is difficult to draw 
generalizable conclusions from these results. The difference in PLC scores 
may be due to the irregularly high MPI 'Life Control' or low 'Pain Severity' 
scores recorded by the control group. They may actually have a more internal 
locus of control because they have less of a pain problem to worry about. 
Locus of control should prove a fruitful line of inquiry for future research on 
this topic. 
No significant main effect was found for time on either scale although 
Main & Parker (1989) found the PLC to be sensitive to change on pain 
management programmes. Their results show that after completing a pain 
management programme individuals show an increase in Pain Control and 
Pain Responsibility scores. Main & Parker's findings are consistent with the 
results that would be expected from a cognitive-behavioural treatment 
programme as the emphasis of such treatments is on re-establishing the 
individual's ability to take control of the pain problem rather than the pain 
problem controlling them. The inability of the currant study to replicate these 
findings may be due to the small sample size used. 
The average scores shown by the control group were higher than the 
results reported by Main & Parker (1989). It may be that the control group 
already showed such high scores on these measures that no improvement 
was possible, while the opioid group failed to improve. If this were the case, 
these results suggest more work would be required on the opioid group to 
enhance their confidence in their ability to cope successfully with chronic 
pain and stabilise their use of opioids. 
Discussion of Cognitive Error Questionnaire (CEQ) Results 
After completing a cognitive-behavioural treatment programme it 
would be reasonable to expect a decrease in cognitive errors as the individual 
begins to experience more adaptive, positive thoughts and a decrease in 
depression. This direction of change was found in the Catastrophisation (lbp) 
and the Selective Abstraction (lbp) subscales where both groups recorded a 
significant reduction in the tendency to make these cognitive errors. 
On the Catastrophisation (general) and the Personalisation (lbp) 
subscales the opioid group increased their rating of cognitive errors, while 
the control group, on average, decreased their levels at post-treatment. These 
two significant interaction effects are interesting as they exemplify a trend 
that is evident in five out of eight of the subscales, although not to a 
significant level. From Table 4 it can be seen that the members of the opioid 
group, on average, actually increased their level of cognitive distortion (even 
though their BDI scores had decreased) at post treatment while the control 
group, as would be expected, decreased their levels on all subscales. One 
possible explanation of this finding is that the realisation by the opioid user 
that their use of opioids has been inappropriate may have caused increases in 
the cognitive distortions that are measured by the CEQ. This finding may 
have major implications for the efficacy of pain management programmes 
for individuals who present with a complicated history of opioid use. 
At the beginning of the treatment programme the members of the 
opioid group appeared to believe that their use of opioids was appropriate. 
By the time they had finished the programme they had been taught that their 
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use of opioids (i.e. uncontrolled doses) was not as good as they had imagined. 
This may have lead to a degree of cognitive dissonance as the individuals 
attempted to incorporate this new information into their self-image. The 
resulting cognitive confusion may have left the individuals in the opioid 
group less amenable to the types of cognitive change normally achieved with 
individuals who complete the treatment programme. This would suggest 
that such individuals need more cognitive therapy than the average 
participant in the pain management programme in order to modify their 
cognitive distortions. More research would need to be conducted in order to 
investigate this speculation. 
Another factor contributing to the inability of these individuals to 
modify their inappropriate cognitions is the fact that many of the members of 
the opioid group appeared to be cognitively impaired during the programme 
due to their uncontrolled dosages of opioids. Several members of the opioid 
group would appear to 'slow down' at certain times of the day and were 
obviously under the effects of drugs. Opioids, when titrated to the pain, cause 
minimal cognitive impairment (Zenz, 1991). However, three members of 
the opioid group were using homebake during the programme and five of 
the seven participants consistently showed signs of cognitive impairment. 
Another unknown quantity was the use of marijuana by members of this 
group. Several members of the staff reported the possible use of this 
substance by group members during the programme. 
The cognitive impairment caused by the inappropriate use of opioids, 
marijuana or Benzodiazepines can inhibit learning and may be a major factor 
in the inability of the opioid group to decrease their inappropriate cognitions. 
In future, if a programme of this nature were to be run, it would be strongly 
recommended that every effort be made to control the availability of these 
96 
97 
substances. Regardless of the causes of these cognitions' resistance to change, 
it would appear that more intensive cognitive therapy than was used in this 
programme is necessary to modify the cognitive distortions exhibited by these 
individuals. 
Generally the results of the CEQ were inconclusive with most of the 
subscales showing no significant main effects. However one interesting 
distinction is the higher level of cognitive errors evident for the questions 
that specifically relate to lower back pain (lbp) situations. This probably 
reflects the respondents' negative feelings towards the areas of their lives 
where pain is a problem, and shows that the depression they report is related 
to the impact of chronic pain (Lefebvre, 1981). 
A study by Smith Follick, Ahern & Adams (1986) reported that 
'Overgeneralisation' was the most common cognitive distortion found in 
people with chronic pain and can lead to the 'spread of disability' into all 
facets of the person's life. From the results presented in Table 4 it can be seen 
that for both the members of the opioid group and the control group they 
scored their highest levels of cognitive distortion for the 'Overgeneralisation 
(lbp )' subscale at both pre- and post treatment. 
The most surprising finding from this questionnaire was that there 
were no main effects for group evident on any of the subscales. According to 
Lefebvre (1981) the opioid group would have been expected to score 
significantly higher on the CEQ subscales as they had significantly higher 
levels of depression ( as measured by the BDI) than the control group. These 
higher levels of depression should mean that the opioid group systematically 
distort the meaning of events so as to consistently construe themselves and 
their experiences in a negative way (Beck, 1976). One reason for this finding 
may be that the 'depression' felt by people with chronic pain is different from 
the normal concept of depression. Many people with chronic pain have 
mood disturbances and feel depressed, but in contrast to other depressed 
people, their mood disturbance is usually one of irritability rather than 
sadness (Sternbach, 1984). 
The lack of distinction between the two groups may be due to the small 
sample size. Another confounding factor influencing the results obtained is 
that the CEQ was found by most participants in the pain management 
programme to be difficult to comprehend. Instructions asking the subject to 
imagine they were in a given situation were especially confusing because of 
the strong 'American bias' on the situations. Compounding this problem, 
those subjects who did not actually have lower back pain were instructed to 
substitute their own condition where the phrase 'lower back pain' was 
mentioned. Subjects also complained about the repetitive nature of the 
questions and the length of time it took to complete. It is strongly suspected 
that more than one subject skipped through the questionnaire. 
Many of the questiqns that were relevant to the participants had to be 
read extremely carefully in order to find the 'cognitive distortion' in each 
situation. In short, this questionnaire was unsuitable, especially when 
administered in conjunction with a variety of other psychometric 
instruments. Unfortunately at the moment there are very few measures of 
cognitive distortion available, as they relate to pain problems. 
Discussion of Coping Strategies Questionnaire (CSQ) Results 
There is growing evidence that coping strategies may be an important 
factor determining how people adjust to chronic pain (Rosenstiel & Keefe, 
1983). It was therefore thought that any difference in the use of coping 
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strategies by the control and opioid group may point to areas that are under-
utilised by people with a complicated history of opioid use. 
The control group reported using the coping strategies of reinterpreting 
pain sensations, ignoring pain sensations and the use of coping self-
statements significantly more often than the opioid group. This may suggest 
that the opioid group uses opioids instead of these coping strategies. 
However the control group had a significantly shorter average pain duration 
than the opioid group. Jensen et al. (1992) suggest that coping strategies are 
used more often, and possibly more effectively, earlier on in the 
development of chronic pain and therefore the differences between use of 
coping strategies, as found by the CSQ, may be due to pain duration rather 
than the use of opioids. 
Another confounding factor is the fact that the control group had a 
significantly lower average pain severity rating, as measured by the MPI. 
Jensen et al. (1992) report that people with a lower pain severity may be more 
likely to find cognitive coping strategies beneficial. This was certainly 
evident when administering these questionnaires. Many members of the 
opioid group just laughed at the thought of 'reinterpreting pain sensations' 
claiming that the pain was 'just there, and nothing could change that'. 
There was a significant decrease in the use of 'Coping Self-statements' 
by both groups although the control group used these coping strategies 
significantly more than the opioid group. This may be an indication that 
other activities, such as relaxation, learnt during the programme have 
replaced these particular coping strategies. 
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There was a significant decrease in the use of 'Praying/hoping' 
strategies by the control group after the completion of the programme. 
Praying/hoping strategies have a 'magical' quality about them. It may be that 
the positive coping strategies learned during the programme gave the control 
subjects more concrete and real ways of dealing with pain rather than relying 
on magical thinking. The fact that the opioid group did not report a 
significant decrease in the use of these 'magical' strategies may suggest that 
they did not develop more positive coping strategies. 
There was also a significant decrease in the 'Catastrophisation' subscale 
for the control group which again, may be an indication that other activities, 
learnt during the programme have replaced this particular negative coping 
strategy. Turner & Clancy (1986) report that the most important factor in 
poor coping appears to be the presence of catastrophising. Rosenstiel & Keefe 
(1983) report that a decrease in catastrophising is correlated with reductions in 
psychosocial impairment. 
The decrease in catastrophising is an especially significant result. 
Rosenstiel & Keefe (1983) suggest that successful coping is a consequence of 
avoiding catastrophising. The reduction in the use of negative strategies 
(such as catastrophising) may be more important to successful coping than 
increasing the frequency of using positive strategies (Turk & Rudy, 1992). 
Due to the potential impact of catastrophising on successful coping with 
chronic pain it is quite surprising that the opioid group did not report a 
significantly higher level of catastrophising than the control group at pre-
treatment. 
The control group, while showing similar levels of catastrophising at 
pre-treatment to the opioid group, significantly decreased their level of 
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catastrophising at post-treatment while the opioid group did not. This would 
suggest that some aspect of the programme was useful to help non-opioid 
users decrease their catastrophisation, but that people with complicated 
history of opioid use need further work in this area. This speculation is 
further supported by the fact that the opioid group did not show a decrease in 
their use of 'Praying/Hoping' strategies. Again this may be a result of the 
cognitive impairment seen in several members of the opioid group. Future 
research in this area could look at why this cognitive-behavioural 
programme did not reduce the opioid group's catastrophisation and how to 
improve this situation. 
Both groups also reported a significant increase in there 'perceived 
ability to control their pain' and 'perceived ability to effectively decrease their 
pain levels'. This is an extremely encouraging result and, in conjunction 
with the increase in MPI 'Life Control' subscale, may suggest that both groups 
have shown an increase in self-efficacy at the completion of the pain 
management programme. If the members of the opioid group perceive that 
they have learned effective alternatives to controlling their pain from their 
participation in the programme, there is an increased probability that they 
will be able to stabilise their use of opioids. 
There is a possibility that the control group were coping with chronic 
pain to a greater extent because they were already using appropriate coping 
strategies. Certainly the control group were using these coping strategies to a 
greater extent than the members of the opioid group. In a meta-analysis of 
the utility of cognitive coping strategies, Fernandez & Turk (1989) found that 
"cognitive strategies, when in comparison to no-treatment or positive 
expectancy alone, reduce pain significantly" (p. 132). Marlatt & Gordon (1985) 
advocate replacing maladaptive habit patterns (the inappropriate use of 
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opioids) with alternative behaviours and skills (in this case coping strategies, 
relaxation and exercise). Future research could be directed towards seeing 
what alternative coping strategies can be utilised by people with a 
complicated history of opioid use and how to decrease their use of negative 
strategies successfully. 
Discussion of PMP Evaluation Questionnaire Results 
There were no significant differences between the answers given by the 
opioid or control groups for any of the pain management programme 
evaluation questions. 
From the results of the questionnaire it would appear that most people 
thought the programme was useful (question 1) and provided useable skills 
(question 2). Although most people were not particularly confident about 
continuing to use these new skills (question 5). 
Most people were not so sure about being able to rely less on their 
medication (question 3) or stabilise their use of medications (question 4). It is 
not clear why the control group would feel this way to a (non-significantly) 
greater extent than the opioid group, but the cautious response by the 
members of the opioid group probably reflects a lack of self-esteem due to a 
number of years on various medications. 
Marlatt & Gordon (1985) have developed a range of maintenance 
strategies for the treatment of addictive behaviours which are relevant to the 
prevention of relapse for individuals who have stabilised or withdrawn from 
opioid medications. The Burwood pain management programme already 
includes a number of maintenance strategies for the typical participant in the 
programme, including plans for dealing with flare-ups, assertiveness training 
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to deal with others and the devising of plans to deal with set-backs. (Nicholas 
(1992) offers a range of strategies to prevent relapse after completion of a pain 
management programme). Individuals with a complicated history of opioid 
use need a set of more specific maintenance strategies to deal with their 
particular problems. 
In order to identify high risk situations for unstable use of opioids a 
therapist-assisted examination of the subjects 'pain and medication usage 
diary' may be useful. Self-monitoring can serve both as an assessment 
procedure and an intervention strategy, since the subjects' awareness of the 
target behaviour increases as assessment continues. Once the high risk 
situations of opioid use have been identified it may be useful to engage the 
subjects in some role playing exercises. For example, the procedure of covert 
modelling (Kazdin, 1976) may be employed to allow the subjects to imagine 
engaging in appropriate coping responses when confronted with a high risk 
situation. 
These individuals should also be taught to view a lapse as a mistake 
and an opportunity to learn about developing more effective coping 
strategies for the future rather than as a personal failure and the end of the 
road. In order to help with this way of thinking a relapse contract may be 
utilised. This involves specifying ahead of time the coping responses that 
should be employed so that the initial lapse does not become a full-blown 
relapse. The utilisation of additional refresher courses or booster sessions to 
prevent relapse should also be considered. 
Although each member of the opioid group has been assigned to a staff 
member as back-up in case they should feel the need to talk to someone about 
any problems they may be experiencing, these other strategies were not 
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incorporated into the opioid programme due to the opioid group having a 
shorter programme than usual. In future, programmes designed to treat this 
challenging group should incorporate specific relapse strategies to aid in 
maintaining stability of opioid use. Refer Marlatt & Gordon (1985) for a 
detailed discussion. Dolce (1987) has suggested that people who fail to display 
increases in efficacy expectancies for coping may constitute a group of people 
who are at higher risk for relapse. Future studies on this topic should also 
provide interventions which specifically target low efficacy beliefs in order to 
improve treatment outcome. 
Most people felt they would definitely recommend the programme to 
others ( question 6) and felt better about themselves since completing the 
programme. These are encouraging results but it must be remembered that 
the post-treatment answers were given on the last day of the programme 
when everyone was feeling positive and the follow-up results were from 
only seven of the thirteen original participants. 
Methodological Issues 
Before discussing the implications of these findings it is necessary to 
consider several confounding factors that may influence any clear 
interpretation of these results. 
Subjects 
One of the main drawbacks with this study is the small number of 
subjects involved and the atypical nature of the control group. These 
problems are both a function of the 'real world' nature of this research. 
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The Opioid Group. One of the surprising aspects of this study was the 
small number of females whose names were submitted for consideration as 
members of the opioid group. Only three names were collected and none of 
them were able to attend. From the literature it does not appear that there 
has been much work done on the effects of gender in identifying a 
complicated history of opioid use. This is an area that may warrant further 
investigation. This may point to a possible selection bias in the opioid group 
to the extent that the people whose names were collected may be more 
readily suspected of having a complicated history of opioid use. Of the people 
who attended the opioid programme four of the seven had visible tattoos 
and health care professionals could naturally be more suspicious of their 
motives for obtaining opioids. 
One possible explanation for the small number of females that were 
identified may be because many people who are identified as opioid 
dependent are also diagnosed as having an Anti-social Personality Disorder 
according to DSM-III-R (American Psychiatric Association, 1987) classification 
criteria. According to Doug Sellman, a consulting psychiatrist with the 
alcohol and drug rehabilitation service in Christchurch, 60% of individuals 
referred to their service who intravenously abuse opioids have diagnosable 
anti-social personality disorders (Sellman, D., personal communication, June 
10, 1992). This disorder is found to occur mainly in males (American 
Psychiatric Association, 1987) and may partially explain the low incidence of 
females referred to the Burwood MSM pain management programme. More 
research may demonstrate whether psychiatric co-morbidity is common in 
people with both chronic pain and a complicated history of opioid use. It is 
certainly common in those with opioid dependance (O'Brien, Woody & 
McLellan, 1984). 
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Related to this issue, health care professionals may be reluctant to 
commit their suspicions of opioid problems to the permanent record of one 
of their patients. Many of the files that were examined for this project made 
no mention of a complicated history of opioid use and it was only by personal 
communication with the referring general practitioner that evidence of a 
problem was established. 
Although the opioid group was initially to be randomly selected, the 
members turned out to be self-selecting by virtue of the fact that many 
individuals whose names were submitted for consideration could not be 
contacted. Flor et al. (1992) suggest that there may be considerable differences 
between those people who accept treatment and those people who decline, 
for whatever reason. One possible selection bias of the study is that the 
people who were recruited may be more settled in their living patterns for 
one reason or another which was reflected in their ability to be contacted. 
The Control Group. The control group used in this study did not 
accurately reflect the normal participant in the Burwood pain management 
programme. These individuals did gain significant benefit from their 
participation in the programme, going by the results of the questionnaires 
that were administered. These individuals may have been relatively well 
adjusted before entering the programme but they received what is referred to 
as a 'booster' by participating. 
At the start of this study it was intended to compare the opioid group 
with the control group in order to look at possible differences between use of 
coping strategies, cognitive distortions, feelings of helplessness and other 
measures that are thought to influence the individual's ability to cope with 
chronic pain. 
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In order to gain more generalizable results from this comparison a 
control group that was similar to the opioid group on a variety of parameters 
(sex, age, pain site, pain duration, socio-economic status, etc.) except for the 
fact that they did not have a complicated history of opioid use would be 
preferred. From the start, it was known that this would not be possible; 
however, it was hoped that the control group would be more representative 
than was the case. 
When comparing the results of the opioid and control groups it must, 
therefore, be taken into consideration that the control group was actually 
coping with chronic pain better than most people who attend the 
programme. While this makes for greater differences between the opioid and 
control groups it does not allow distinctions to be drawn between the opioid 
group and the 'typical' individual who is referred to the programme for the 
scales that are not usually administered to participants in the pain 
management programme. 
Pain Management Programme 
Another difference between the opioid and control group was the 
actual pain management programme that the members of each group 
participated in. The members of the opioid group had a full day less than the 
control group on the programme due to Easter. Also, due to the Easter break, 
the post-treatment questionnaires were given to the two groups after they 
had engaged in different activities. One of the control group members 
reported that because of the busy schedule of activities on a Friday the 
answers the group had given to the questionnaires were influenced by an 
increase in pain due to that morning's activities. 
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The education sessions that are run as part of the programme are quite 
informal and encourage contributions and feedback from participants. 
During these discussions the members of the opioid programme invariably 
turned the discussion to the subject of opioids during the first half of the 
programme. This is to be expected due to the nature of this group but it was a 
subtle difference in the programme that each group participated in. It is 
interesting to note that this continual reference to opioids had stopped by the 
end of the programme. It is assumed that this was due to a decrease in focus 
on the use of opioids by these individuals. 
The programme that the control group participated in was different 
from that which the opioid group attended and also from the 'average' 
programme. The Burwood pain management programme is designed to 
meet the particular needs of the individuals that are participating in it. As 
the members of the control group were coping with chronic pain better than 
most individuals that attend the programme, there was less emphasis on 
decreasing levels of distress and more emphasis on such aspects as vocational 
guidance. 
Missing Values 
A further complication of this study was the high levels of non-
compliance shown by both the control and opioid groups when it came to 
filling out these questionnaires. Although every attempt was made to get all 
subjects to answer all the questions this was unsuccessful. 
During all the questionnaires subject #11 refused to answer any 
questions that were 'objectionable'. For example the Coping Strategies 
Questionnaire contained a number of items dealing with the individuals' use 
of 'Faith in God' as a coping strategy, this was thought to be "none of my 
business". Subject #11 subsequently failed to attend the follow-up session 
after several arguments with staff members during the programme. 
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Several subjects (including subject #11) refused to answer questions 
regarding the responses of 'significant others' to their pain behaviours from 
the Multidimensional Pain Inventory, claiming they had no significant 
others to report on. Only subject #3 was consistent in this respect over all 
three testing sessions. On the last day of the pain management programme 
Subject #6 left early claiming that the completed Cognitive Error 
Questionnaire would be dropped in to Burwood the following week. As this 
subject has not been heard from since, the follow-up results for this subject 
are also unavailable. 
At the 2 month follow-up subject #12 also failed to turn up and subject 
#5 refused point blank to fill in any questionnaires. Of those who did attend 
the two follow-up sessions four out of the nine refused outright to complete 
the Cognitive Error Questionnaire (two from the opioid group and two from 
the control group). While two of the nine failed to complete the 'Pain 
Management Programme Evaluation Form'. 
Flor, Fydrich & Turk (1992), in a meta-analysis of the efficacy of pain 
clinics found that there was substantial attrition of subjects especially at long 
term follow-up, with some studies reporting "as many as 87% did not 
complete the entire study" (p. 227). Reports such as this put these drop-out 
rates in perspective. Before this study it was anticipated that members of the 
opioid group may drop-out or not be available at follow-up, however it was 




The psychometric instruments used in this study were chosen for two 
purposes. First, in an attempt to see if a programme of this type could help 
individuals with a complicated history of opioid use. The scales are meant to 
assess empirically if the individuals actually did 'improve'. Secondly, the 
scales used were chosen so as to investigate specific factors that it was thought 
may differ between individuals that have a problem with opioids and those 
that do not. 
Although there has been a rapid expansion of theoretical models and 
clinical interventions the assessment of pain and people with pain has 
lagged behind (Turk & Rudy, 1986). The psychometric instruments used in 
this study purport to measure unique cognitive constructs but more work is 
needed to establish the independence of these instruments and the influence 
of other confounding factors, such as mood states, on these self-report 
measures (Turk & Rudy, 1992). New assessment techniques that are 
theoretically based on the increasing amount of research into this area need 
to be developed. 
The psychometric instruments that were used in this study could not be 
administered on a regular basis to all participants in the pain management 
programme as they are also too time-consuming. As mentioned earlier, a 
scale needs to be developed that encompasses all the variables that the 
present scales measure. Guidelines for the development of such a scale have 
been suggested by Turk & Rudy (1986). 
The high number of questionnaires administered relative to the small 
number of subjects increases the probability of making Type 1 errors (Keppel, 
1982). However, as this study was the first of its kind it was felt that such a 
large number of measures was justified in order to explore which measures 
were appropriate. 
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Another confounding influence inherent in this type of study is the fact 
that the results reported for each test are influenced by how the individual 
felt at the moment the test was administered. For example, the difference in 
baseline (pre-treatment) measures and post-treatment measures could simply 
reflect the natural fluctuations in a chronic condition rather than the effects 
of treatment. The 'Pain and medication usage diary' was to be used as a 
means of controlling for this problem and future studies should include 
suitable long-term measures such as performance over time of certain 
behaviours. 
General Conclusion 
One of the more surprising findings of this study is how similar the 
opioid group was to the average participant in the pain management 
programme (as represented by the database) on the MPI subscales. One 
tentative conclusion that may be drawn from this discovery is that the MPI 
does not measure the variables that are contributing to a complicated history 
of opioid use. The one major difference was the level of depression evident 
in the opioid group, although the members of the opioid group were not 
significantly more depressed than the data base comparison. However, not 
everyone who is depressed has a problem with opioids so it would appear 
that other factors are involved. From the results of the questionnaires that 
were used it would appear that there was no major differences in the level of 
cognitive distortion shown by the opioid and control groups, although the 
opioid group would appear to be less amenable to change. This result was 
also found with the negative coping strategies, such as catastrophisation, on 
the CSQ. 
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We emerge with a picture of a group of people that have no medical or 
cognitive reasons, as assessed by our measures, to be any different from the 
average participant in the pain management programme, and yet they are 
presenting with serious problems with their use of opioid medications. 
Although the opioid group members were similar at pre-treatment to the 
average participant they showed more resistance to change on several 
measures (for example, the CSQ 'Catastrophisation' subscale) than the control 
group members. Future research into the subject of who is likely to develop 
a complicated history of opioid use will need to draw from the field of 
addiction studies. 
From the social learning perspective addictive behaviours are not 
caused by an underlying physiological disorder or the chemical action of the 
substance. Rather the determinants of addiction lie in situational and 
environmental antecedents, beliefs and expectations and the individual's 
family history and prior learning experiences with the substance (Marlatt, 
1985). 
Factors that have not been considered here, but that are probably 
involved in the development of a problem with opioids, include the attitude 
towards using opioids of the individual concerned, their peers, family and 
relevant health care professionals. The lengths to which the individual is 
personally prepared to go to achieve pain relief is also a consideration. Peele 
(1977) suggests that people's values are crucial in determining who becomes 
and remains addicted and who chooses not to do so. That is, people make a 
choice (although not necessarily at a conscious level) of what ends they are 
willing to go to in order to gain relief from pain. 
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The presence of psychopathology would also have an impact on the 
development of a complicated history of opioid use. O'Brien, Woody & 
McLellan (1984) suggest, from a review of the literature,that 74% of opioid 
dependant subjects (without chronic pain) at treatment meet DSM III criteria 
for a lifetime diagnosis of an affective disorder and 40-50% have Antisocial 
Personality Disorder. O'Brien et al. further suggest that such individuals 
generally have poor treatment results from rehabilitation programmes, 
unless long-term therapy is provided. 
Research should also be directed towards discovering the consequences 
for the individual of inappropriately using opioids. This will lead to a better 
understanding of the reinforcing factors that lead to increased use and the 
negative consequences that may serve to inhibit the behaviour. If controlled 
use of opioids is to be a viable treatment option for individuals with a 
complicated history of opioid use, research will also need to be conducted to 
investigate which individuals are capable of maintaining stability. Although 
there are many differences between the controlled use of opioids and the 
controlled use of alcohol, the predictors of controlled drinking may provide a 
starting point for research into this area. Heather & Robinson (1981) in a 
review on this issue suggest that the presence of social support following 
treatment, the clients confidence about their ability to stabilise, a low severity 
of drinking symptoms and shorter history of problems contribute to 
controlled drinking. In a more recent review, Rosenberg (1993) has included 
the psychological and social stability of the individual as good predictors of 
controlled drinking. 
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Another factor that may be involved in the development of a 
complicated history of opioid use is the level of perceived disability 
experienced by the individual. Main & Parker (1989) have reported that the 
person who displays problems with opioids is more likely to feel more 
disabled than the average participant in a pain management programme. 
The Sickness Impact Profile (Bergner, Bobbitt, Carter & Gilson, 1981) was 
going to be included in the battery of measures given to each subject but it 
was felt that enough questionnaires were already being used. The level of 
perceived disability may be an important area for future research. A study by 
Smith Follick, Ahern & Adams (1986) reported that cognitive distortion (as 
measured by the CEQ) is closely related to disability (as measured by the SIP). 
The concept of perceived disability is related to catastrophisation. 
While both groups did show significantly lower levels of catastrophising 
distortions on the CEQ (lbp) subscale at post-treatment the results of the 
other two catastrophising subscales a:re interesting. While the opioid and 
control groups showed similar scores of catastrophising on the CSQ and CEQ 
(gen.) catastrophising subscales at pre-treatment the control group 
significantly decreased their scores at post-treatment. The opioid group did 
not show any significant decrease on the CSQ while they actually showed a 
(non-significant) increase in cognitive distortions on the CEQ (gen.) subscale 
at post-treatment. 
The difference between these two scales is that the CEQ subscales look at 
the internal cognitive distortions of the individual, while the CSQ looks at 
the actual results of these distortions, that is the coping strategies that are 
employed. It would appear that the inability to decrease catastrophising as a 
coping strategy may be due more to general catastrophising in the individuals 
life, rather than catastrophising specifically related to the pain problem. This 
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would suggest that the individuals who show a complicated history of opioid 
use are catastrophising about their lives in general and therefore more 
general cognitive therapy would be necessary to treat these individuals. 
The most important factor in poor coping with pain appears to be the 
presence of catastrophising (Heyneman, Fremouw, Gano, Kirkland & 
Heiden, 1990; Turk & Rudy, 1992). While it is surprising that both groups 
showed similar levels of catastrophising at pre-treatment, the fact that the 
opioid group did not show any reduction in catastrophising would tend to 
suggest that their cognitions are more resistant to change. Future research 
should be directed towards ways to enhance decreases in catastrophisation in 
this challenging population. 
Although the results of the PLC are inconclusive, due to the 
abnormally high levels of MPI "Life Control' exhibited by the control group, 
this is still an area which deserves greater attention in future studies. The 
fact that the opioid group, on average, showed low levels of confidence in 
their ability to stabilise their use of medications, as reported by their PMP 
Evaluation Questionnaire results, means that more attention will need to be 
paid to developing a sense of self-efficacy and foster the idea that they are in 
control of their opioid use. Several studies have highlighted the crucial role 
that perceived self-efficacy plays in controlling pain (Bandura et al., 1987). 
Kores, Murphy, Rosenthal, Elias & North (1990) report that self-efficacy 
beliefs are associated with level of functioning and response to treatment in a 
pain management programme, while self-efficacy is also an important factor 
in self-regulation of addictive habits (e.g. smoking, DiClimente (1981)). 
Dolce, Crocker, Moletteire & Doleys (1986) found higher levels of self-
efficacy expectations to be related to greater reductions in the need for pain 
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medication. Although no actual measures of self-efficacy were used in this 
study the 'Life Control' subscale of the MPI approximates self-efficacy in the 
context of pain (Fernandez, E., personal communication, August 10, 1992). 
Our results indicate that, although the opioid group showed slightly lower 
scores on this subscale than the data-base comparison at pre-treatment, by 
post-treatment both groups had significantly increased their scores to the 
same level. This result is confirmed by the CSQ results. Both groups also 
reported a significant increase in there 'perceived ability to control their pain' 
and 'perceived ability to effectively decrease their pain levels'. This increase 
in self-efficacy does not seem to have carried over to the use of opioids. 
Future research in this area should develop a specific self-efficacy scale to 
measure opioid use and pain control [see Bandura (1982) for the single 
response format recommended for assessing self-efficacy]. 
Despite the atypical nature of the control group important preliminary 
conclusions can still be drawn. The control group was atypical and therefore 
difficult to compare to the opioid group, while not all members of the opioid 
group appeared to make substantive gains in functioning. However the 
study itself was an attempt to positively address the problems faced by 
individuals who present with chronic pain and a complicated history of 
opioid use. These people can not be expected to increase their feelings of self-
worth, which is necessary to break the 'addiction' cycle, when they are treated 
so negatively by the people that are supposed to help them. The members of 
the opioid group reported that the general staff at Burwood Hospital acted in 
a hostile manner towards them when they went for meals in the staff 
cafeteria. This reflects the influence that perjorative labels can have on the 
way other people interact with individuals with a complicated history of 
opioid use. 
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It is not really appropriate to refer to 'the opioid group' as if its members 
are a homogeneous sub-group of pain sufferers, which has been referred to as 
the 'pain-patient uniformity myth' (Turk, 1990). Each member of the group 
was an individual and some people gained a lot from their participation 
while others did not. The literature suggests that people with a complicated 
history of opioid use should be withdrawn from their medication before 
treatment starts. The literature is not so clear on what to do if the individual 
does not wish to discontinue opioid medication. All the members of the 
opioid group expressed a willingness to stabilise their use of opioids, as part 
of their consent form. [Although they were hardly likely to say otherwise!] It 
would be naive to suggest that all such individuals do wish to do something 
about their complicated history of opioid use. This study has attempted to 
show that certain individuals with a complicated history of opioid use and a 
genuine interest in helping themselves, may be maintained on opioids, 
contrary to the literature. 
Several members of the opioid group did achieve a significant 
improvement in functioning. A study by Tulkin et al. (1990) suggests that 
successful completion of a pain management programme leads to a decrease 
in the individuals utilisation of medical services with a resultant decrease in 
costs to the health care system. The Burwood MSM pain management 
programme estimates that it only needs one 'success' per programme to cover 
the costs of running the programme. This target was achieved by the 
members of the opioid group. Obviously it is impossible to say this 
individual 'passed' and that individual 'failed' especially as their are no 
universally accepted criteria for evaluating the outcome of pain management 
programmes (Turner & Ramano, 1984). But, as indicated by the clinical 
observations, three individuals gained significant benefit from attending the 
programme. The enduring memory of this programme for the coordinator 
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of the Burwood MSM pain management programme was that at the 
beginning of the programme, all the members of the opioid group could talk 
about was opioids. By the end of the programme these individuals had to be 
reminded about their use of these analgesics. 
One interesting result from this study is that two members of the 
opioid group who had their medication increased are no longer displaying 
signs of inappropriate opioid use. This is consistent with a report by Zenz 
(1991) who notes "We have .... treated some patients who were addicted to 
medical opioids caused by an 'as required'-regimen. They lost all their 
addictive behaviour as soon as they were treated in the right way - by an 
effective dose at regular time intervals" (p. S101). Berntzen & Gotestam 
(1987) report that a fixed-interval analgesic schedule was found to be more 
effective than an on-demand analgesic schedule in reducing subjective pain. 
A significant component of the drug education component of the opioid 
group's programme was explaining the analgesic benefits of time-contingent 
analgesic regimes. 
An alternative explanation of this finding is that, as mentioned in the 
introduction, the iatrogenic syndrome of 'opioid pseudoaddiction' is 
occurring, that is, people are perceived as displaying drug seeking behaviour 
as a result of inadequate analgesia. In the case of these two individuals a 
definite history of intravenous opioid use was established but this 
consideration must be recognised in the management of individuals with a 
complicated history of opioid use. 
Although the 'Pain and medication usage dairies' were not completed 
satisfactorily some brief comments about the results that were obtained are in 
order. Most members of the opioid group were taking their opioids on a 
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p.r.n. ('as required') basis. This can lead to problems of increasing doses and 
'mini-withdrawals' leading to even more pain (refer Introduction). The goal 
of the programme was time-contingent use of analgesia, which represents 
'stability'. It would have been interesting to see if there were any differences 
between those that had achieved stability in their use of opioids and those 
who had not. The sample used in this study was unfortunately too small to 
attempt to answer these interesting questions. However, they should prove 
to be fruitful lines of inquiry for future research. 
A therapist-assisted examination of the individual's diary may also 
have lead to the identification of high-risk situations of inappropriate opioid 
use. This is a major component of relapse prevention and may lead to a 
greater understanding of the causes and problems associated with these 
individuals' use of opioids. 
All members of the opioid group reported believing that their 
medication was inadequate to control their pain. In conjunction with high 
levels of personal distress, these beliefs appear to readily lead to behaviour 
such as self-medication with opioids used intravenously. Although these 
factors 'sow the seeds' of potential abuse it is the personal lengths an 
individual is prepared to go to in order to gain pain relief that is the 
important factor in predicting the development of a complicated history of 
opioid use. The individuals values are crucial in deciding the extent to 
which they will engage in any behaviour (Peele, 1989). Both the individuals 
who discontinued self-medicating expressed a desire to stabilise their 
medication due to the fact that their family relationships were suffering. 
This highlights the fact that the individual must have a genuine interest in 
helping themselves before any such treatment programme can be successful 
(Marlatt, 1985). 
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Addiction, when not complicated by psychological factors, is extremely 
rare in people with chronic pain who are prescribed opioids (Melzack, 1988). 
As discussed previously, psychological and behavioural symptoms of chronic 
pain are not amenable to opioid medications. This suggests that before an 
individual is placed on opioid therapy a thorough multi-disciplinary 
assessment by a specialised team should be conducted. Any psychological 
complications can then be dealt with before a co-morbity develops (refer 
Schug, Merry, & Ackland (1991) for proposed guidelines of opioid 
maintenance therapy in New Zealand). In particular, people with Antisocial 
Personality Disorder are unamenable to Cognitive-Behavioural treatment 
(Sellman, 1992). Any future guidelines for the use of opioid therapy should 
consider this point carefully. However a note of caution is needed in the 
diagnosis of psychological or psychiatric contributions to chronic pain. 
"After it is believed that all appropriate (and minimally invasive) 
investigations have been completed, a patient should not be diagnosed 
as having pain that is either caused by or made worse by psychologic 
illness unless positive evidence of that illness, acquired by psychiatric or 
psychologic evaluation, has been denwnstrated and a sufficient cause for 
it has been found' (Merskey, 1990, p. 326). 
The presence of a psychiatric disorder per se should not be seen as a 
contraindication of opioid maintenance therapy. Several studies have 
shown no evidence of drug seeking behaviour by such people. For example 
France et al. (1984) report that of 16 people they kept on long-term opioid 
therapy, six had dysthymic disorder and six had a major depressive disorder 
according to DSM III criteria. There was no indication of drug-seeking 
behaviour in any of these individuals. This general finding is supported by 
Kennedy & Crowley (1984) and Bouckoms et al. (1992). 
Concluding Comments 
121 
Adequate evaluation and management strategies should lead to a 
reduction in the number of individuals showing co-morbid opioid 
dependency and chronic pain. For those individuals that do show these 
signs, a new management strategy has been suggested based on cognitive-
behavioural theories for the treatment of chronic pain and addictions. The 
fact that, on average, all members of the opioid group showed significant 
decreases in depression scores (except Subject 1), higher levels of life control, 
lower levels of interference and affective distress and increases in outdoor 
work suggest that nearly all the participants gained some benefit from 
attending the programme. The incorporation of relapse prevention 
techniques and an increased focus on decreasing catastrophisation and 
increasing self-efficacy may lead to the provision of positive management 
strategies for this challenging population. This in turn would suggest that 
the mandatory discontinuation of opioids, as suggested by the literature, may 
not be absolute. 
The findings of this study that these individuals may be more resistant 
to change on such cognitive variables as maladaptive coping responses and 
cognitive distortions would suggest that more intensive treatment may be 
necessary. The implications of these results are that extra resources may be 
needed to treat complex cases such as these. This in turn implies that the 
political will must be there to seriously address these issues. 
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From the results of the comparison of the opioid group with the MSM 
database it can be seen that in most respects the two groups reported similar 
scores at pre-treatment and similar improvements in scores at post-treatment 
on the MPI and BDI. Appropriate initial goals for individuals with this 
history and chronic pain appear to include stability of use and a change from a 
p.r.n. basis to time contingent use. The fact that demonstrable change in this 
previously considered untreatable group could be shown is indicative that 
further study should be carried out. It is hoped that refinement in methods 
for treating co-morbid chronic pain and opioid dependency will ensue. 
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THREE WEEK MUSCULOSKELETAL PROGRAMME 
MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY 
8:00 To 8:30 NURSING LIASON SESSION 
8:30 To 10:00 8:30 To 9:30 8:30 To 10:00 8:30 To 9:00 8:30 To 9:30 
Fitness Group Session Exercises 
Nursing Gym (Psychologist) 9:00 To 9:30 Nursing 
Relaxation 
Tape 
10:00 To 10:30 9:45 To 10:00 10:00 To 10:30 9:30 To 10:00 9:30 To 10:00 
Morning Tea Morning Tea Fitness/Pool Fitness/Pool Fitness/Pool 
10:00 To 11:30 10:30 To 11:00 10:00 To 10:30 10:00 To 10:30 
Group Morning Tea Fitness/ Gym Morning Tea 
10:30 To 12:00 Session 
Diet/Pharm 
Group 11:45 To 12:15 11:00 To 12:00 10:30 To 12:00 10:30 To 11:30 
Session Community Doctor's 
withO/T Fitness /Pool Resources Education Fitness/ Gym 
Session Session 
12:00 To 12:30 12:30 To 1:00 12:00 To 12:30 12:00 To 12:30 11:30 To 12:30 
Lunch Lunch Lunch Lunch Nursing 
1:00 To 2:30 12:30 To 2:00 1:00 To 1:30 12:30 To 1:00 
Group Video/ Walk Lunch 
Session Education (Fitness) 
12:45 To 1:45 with O.T. 
Fitness 2:00 To 2:30 1:30 To 3:00 1:00 To 2:30 
2:30 To 3:00 Relaxation Group Session Group 
Afternoon Training (psychologist) Session 
Tea (Social 
Worker) 
3:00 To 3:30 2:30 To 3:00 
2:00 To 4:20 3:00 To 3:30 2:30 To 4:20 Afternoon Afternoon 
O/T Relaxation O.T. Tea Tea 
Activities Training Activities 3:30 To 4:00 3:00 To 4:00 
Relaxation Recreational 
Training Swimming 
VISITING AFTER 5pm 
7pm To 9pm 7pm To 9pm 7pm To 9pm 






Reason for the project: 
As part of the Musculoskeletal Medicine pain management programme we 
are doing some research to see how good the programme is at helping people 
with their medication usage. 
Your task in this project: 
You have been selected to participate in a control group. The programme that 
was run last month was especially for people who use opioid medications and 
we would like to compare the results of their programme with the group 
results of your programme. 
You will be asked to fill out some extra questionnaires before and after the 
pain management programme as well as a 'pain and medication usage diary'. 
These questionnaires are not a part of the standard programme but will be 
useful not only to evaluate the effectiveness of the programme but also to 
provide valuable additional information about your situation. 
Whether you choose to participate in this research or not it will have 
absolutely no effect on the commencement date of the programme you have 
already been allocated to. You are free to refuse to participate in this study or 
to withdraw at any time, this decision will have no influence on any future 
treatment you will receive. 
Time required: 
The questionnaires should take about two hours to complete on two separate 
occasions. The pain and medication usage diary should take a total of about 10 
minutes a day for 7 weeks to complete. 
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A time and place that is suitable to you will be arranged to complete the 
questionnaires and learn how to fill in the 'pain and medication usage diary'. 
Confidentiality: 
Any information obtained about you from this research will be kept 
confidential. In order to protect confidentiality, code numbers, not names, 
will be used on all forms and in all computer files. Your identity will not be 
revealed in any description or publication of this research. 
Please tick one of the following: 
__ I do want the results of my questionnaires sent to my General 
Practitioner. 
__ I do not want the results of my questionnaires sent to my 
General Practitioner. 
Name of researcher: Mark Turner 
I have read and understood the consent form. I agree to participate in the 
project described above, on the understanding that if at any time I wish to 
withdraw from the experiment I may, without prejudice, do so. All 
information collected will be confidential as will the identity of participants. 
Name: ..................................................... . 
Signature: .............................................. .. Date: 
Witnessed by: ......................................... . Date: 




Reason for the project: 
As part of the Musculoskeletal Medicine pain management programme we 
are doing some research to see how good the programme is at helping people 
with their medication usage. 
Your task in this project: 
Your name has been selected from the waiting list of people who are about to 
enter the Musculoskeletal pain management programme. If you agree to take 
part in this research you will be asked to answer some extra questions that are 
not a part of the normal programme. The questions will be based on the types 
of drugs that you are taking for your pain management and how and why you 
use them. In addition you will be asked to fill in a pain and medication usage 
diary. 
You are free to refuse to participate in this study or to withdraw at any time, 
this decision will have no influence on any future treatment you will receive. 
Time required: 
The questionnaires should take about two hours to complete on three separate 
occasions: Once before you commence the Musculoskeletal pain management 
programme and again at the completion of this programme. Additionally, the 
questionnaires may be given 6 months after your completion of this 
programme to see if the effects are long lasting. A time and place that is 
suitable to you will be arranged to complete the questionnaires. The pain and 
medication usage diary should take a total of about 10 minutes a day for 7 
weeks to complete. 
143 
Confidentiality: 
Any information obtained about you from this research will be kept 
confidential. In order to protect confidentiality, code numbers, not names, 
will be used on all forms and in all computer files. Your identity will not be 
revealed in any description or publication of this research. 
Please tick one of the following: 
I do want the results of my questionnaires sent to my General 
Practitioner. 
I do not want the results of my questionnaires sent to my 
General Practitioner. 
Name of researcher: Mark Turner 
I have read and understood the consent form. I agree to participate in the 
project described above, on the understanding that if at any time I wish to 
withdraw from the experiment I may, without prejudice, do so. All 
information collected will be confidential as will the identity of participants. 
Name: ...................................................... . 
Signature: ............................................... .. Date: 
Witnessed by: ......................................... .. Date: 
Researcher: ............................................. . Date: 
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Appendix 3 
Pain Locus of Control Scale (PLoC) 
P.L.o.C. 
INSTRUCTIONS 
This is a questionnaire to find out how you see the causes and control of your 
pain. 









Please rate each statement by marking "X" in the box which best shows how 
much you currently feel the statement applies to you. 










































































































































16. I can reduce my pain if I imagine a situation in which I have been pain-

















































Three Week Pain Management Programme 
Evaluation Questionnaire 
1. How much use was this programme to you? 
1 ___ 2 ___ 3 ___ 4 ___ 5 ___ 6 ___ 7 
no use some use very useful 
Comments: 
2. Was this programme able to provide you with useable skills to help you 
control your pain? 
1 ___ 2 ___ 3 __ 
not at all somewhat 
4 _______ 5 ___ 6 ___ 7 
very much so 
List skills most valuable to you and any comments. 
------------------------------------------------------------------------
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3. Do you think, as a result of the programme, there has been a change in how 
well you are able to cope with your pain without relying so much on the use 
of medications? 
rely less on 
medication 
1 ___ 2 _______ 3 __ 4 _______ 5 _______ 6 _______ 7 
no change rely more on 
medication 
150 
4. Do you feel more confident in your ability to stabilise your medication as a 
result of this programme? 
1 _______ 2 _______ 3 _______ 4 _______ 5 _______ 6 _______ 7 
very confident 
Comments: 
somewhat not at all 
confident 
5. How confident are you that you will keep doing the things you have learnt? 
1 
very confident 
__ 2 _______ 3 _______ 4 __ _ 5 6 7 
somewhat 
Comments: 
not at all 
confident 
6. Would you recommend this programme to others? 
never 
Comments: 
1 _______ 2 _______ 3 _______ 4 
maybe 
__ 5 _______ 6 _______ 7 
definitely 
7. Do you feel better about yourself now that you have completed the 
programme? 
1 2 4 5 6 
15 1 
7 
not at all 
3 
somewhat very much so 
Comments: 
8. Are there any activities you will do after leaving that you would not have 
done before the programme? 
Comments: 
Thank you for completing the questionnaire. 
Subject No. 
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Daily Pain and Medication Usage Diary 
Pain Severity Scale 
Date No pain 0---10 unbearable pam. 
Mood before Alternative nain control Med:tVPe Med: amount Situation (in which med. taken) Mood after 
- . 
-
Pain after 
> 
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